Methodical aspects of urinary metabolomics by liquid chromatography-mass spectrometry by Vogl, Franziska C.
Methodical aspects of urinary  
metabolomics by liquid chromatography 
- mass spectrometry 
 
 
Dissertation 
 
zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.) an der 
Naturwissenschaftlichen Fakultät IV 
-Chemie und Pharmazie- 
der Universität Regensburg 
 
 
 
 
 
 
 
 
 
 
vorgelegt von 
 
Franziska C. Vogl 
 
aus Eggenfelden 
 
im Jahr 2019 
 
 
 I 
 
Diese Doktorarbeit entstand in der Zeit von Juli 2012 bis August 2018 am Insti-
tut für Funktionelle Genomik an der Universität Regensburg. 
 
 
Die Arbeit wurde angeleitet von Prof. Dr. Peter J. Oefner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Promotionsgesuch eingereicht am: 12.04.2019 
 
 
 
 
 II 
 
 
 
 
 
 
 
Für meine Eltern 
 III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 IV 
 
Danksagung 
 
So, nun ist es soweit und ich darf endlich all denjenigen Menschen meinen 
Dank aussprechen, die maßgeblich dazu beigetragen haben, dass ich diese 
Arbeit fertig stellen konnte. 
An erster Stelle gilt mein Dank Prof. Dr. Peter J. Oefner, der mir es ermöglicht 
hat, an seinem Lehrstuhl diese interessante Arbeit zu verfassen. Vielen Dank 
auch für die Übernahme des Erstgutachtens. Die Möglichkeit auf internationalen 
Konferenzen Erfahrung sammeln zu dürfen, sowie die fachliche Begleitung und 
Unterstützung habe ich sehr geschätzt.  
Vielen Dank auch an Prof. Dr. Frank-Michael Matysik, der sich bereitwillig als 
Zweitgutachter zur Verfügung gestellt hat.  
PD Dr. Katja Dettmer-Wilde möchte ich danken für die Bereitschaft als Dritt-
prüfer und die fachliche Betreuung. Danke für deine Geduld, deine konstruktive 
Kritik und dein offenes Ohr in jeder Lebenslage. Mit deinem unendlichen 
GC/LC-MS Wissen hattest du immer einen passenden Tipp parat, der mir wei-
tergeholfen hat. Ohne dich, hätte ich nicht gewusst, dass „nach zu, ab kommt“ 
und was der Unterschied zwischen Schraubenschlüssel und Schraubenzieher 
ist. Es hat wahnsinnig Spaß gemacht, mit dir gemeinsam am Maxi zu schrau-
ben und dabei manchmal sogar alle Teile wieder richtig verbaut zu bekommen. 
Nur die Namensgebung deiner Spielgefährten (Georg, Metti, etc.) war am An-
fang etwas verwirrend für mich. Unvergesslich bleibt für mich auch „Pinky and 
the Brain“ und deine CSI Einlage.  
Des Weiteren möchte ich Prof. Dr. Antje Baeumner danken für die Übernah-
me des Prüfungsvorsitzes.  
Ein ausdrücklicher Dank geht auch an die Nachwuchsförderung der Universität 
Regensburg für die Promotionsabschlussförderung, die ich für die Fertigstellung 
meiner Dissertation erhalten habe.  
Bei Prof. Dr. Wolfram Gronwald, bedanke ich mich für die fachlich sehr kom-
petenten Ratschläge und den Einblick in die Welt der NMR. An das gemeinsa-
me Skifahren erinnere ich mich gerne zurück. 
 V 
 
Für die gute Zusammenarbeit, die gemeinsame Publikation sowie den immer 
guten Informationsaustausch möchte ich Dr. Peggy Sekula recht herzlich dan-
ken.  
Es war mir eine Ehre Dr. Magda Waldhier kennen gelernt zu haben. Die ge-
meinsamen Yogaabende waren immer sehr gesprächig und lustig. Und auch 
durch die Niederbayern Fraktion, bestehend aus Dr. Christian Wachsmuth 
und Raffaela Berger hab ich mich wie zu Hause gefühlt. Ihr wart meinem nie-
derbayrischen Dialekt gewachsen und habt  auch das besondere bayrische Lob 
„basst scho“ richtig deuten können. Die entstandene und bis heute bestehende 
Freundschaft mit euch Dreien bedeutet mir sehr viel.  
Ein besonderes Dankeschön auch an Dr. Helena Zacharias, Jochen Hoch-
rein, Franziska Taruttis und PD. Dr. Julia Engelmann die mir bei jeglichen 
statistischen und programmier-technischen Problemen zur Seite standen.  
Danke an „Pinky“ alias Nadine Nürnberger. Du warst unser farbiger Stern im 
sonst eher tristen Laboralltag. Leider hat es dich wieder in die Heimat gezogen. 
Deine Geburtstagsparty mit Tortenschlacht ist jedenfalls legendär. Das Küken, 
Claudia Samol, hat jede Mittagspause zum spannenden Erlebnis gemacht. Als 
unermüdliche „Pippettöse“ und „Vorthexe“ war es toll mit dir im Labor zu arbei-
ten, auch wenn die Aliquotierung der Urinproben nie enden wollte. Bei der gu-
ten Seele, Lisa Ellmann, bedanke ich mich auch recht herzlich für die Hilfestel-
lungen im Labor, vor allem für die Zeit, als ich nicht mehr ins Labor durfte und 
du meine etwas komplizierten Anweisungen interpretieren musstest.  
Dem „PC-Betreuer vor Ort“ Christian Kohler möchte ich besonders Danken. 
Du hast dich immer sofort um alle meine kleineren und auch größeren Compu-
ter Probleme und Problemchen gekümmert. Und auch bei der Namensgebung 
deiner Tochter hast du alles richtig gemacht.  
Meinen Kaffee Buddies Dr. Jörg Reinders und Dr. Yvonne Reinders, möchte 
ich auch noch danken. Ihr hattet immer Zeit für ein Gespräch, sowohl fachlicher 
als auch privater Art. Eure kulinarische Verpflegung war ein Highlight, in deren 
Gunst wir des Öfteren bei so manchen Grillpartys kamen.    
Für das sonnige Gemüt, die heitere, aufbauende Art und auch dafür, dass du 
immer einen Übernachtungsplatz hattest, bedanke ich mich bei Elke Perthen.  
 VI 
 
Den beiden NMR-lern, Dr. Trixi von Schlippenbach und Dr. Philipp Schwarz-
fischer, sowie den alten Hasen Dr. Nadine Assmann, Dr. Matthias Klein und 
Dr. Martin Almstetter, die mir vor allem am Anfang sehr geholfen haben, 
möchte ich danken.   
Bei Dr. Thomas Stempfl  und Dr. Christoph Möhle bedanke ich mich für das 
Asyl am Ende meiner aktiven Zeit am IFG. Mit euren Labordamen, Jutta 
Schipka und Susanne Schwab, waren so manche Mittagspausen im Nu vor-
bei. Und auch die beiden Organisationstalenten Eva Engl und Sharon Peter-
sen möchte ich noch dankend erwähnen. 
Allen ehemaligen und aktiven Kollegen am IFG danke ich für die schöne und 
lehrreiche Zeit an die ich mich gerne erinnere.  
Mein besonderer Dank geht an Marianne Felixberger. Nicht nur als Oma von 
Marie bist du immer für uns da. Du hast mir den Rücken frei gehalten und mich 
motiviert, damit ich diese Arbeit fertig stellen konnte. Danke für alles.  
Meinen Eltern Gisela und Wolfgang Vogl, sowie meiner Lieblingsschwester 
Alexandra Lehner gebührt der größte Dank. Ohne euren Rückhalt hätte ich 
diese Arbeit nicht zu Ende gebracht. Kein Jammern und Klagen meinerseits war 
euch zu viel. Kein Weg zu weit, um mir zu helfen. Ihr habt mich bedingungslos 
unterstütz. Ihr könnt euch nicht vorstellen, wie wichtig das für mich war. Einer 
für alle und alle für einen!  
Johannes und Marie, ihr seid mein Ein und Alles, mein Fels in der Brandung. 
Ihr wart immer verständnisvoll, wenn ich mal wieder wegen meiner Doktorarbeit 
keine Zeit für euch hatte. Das hat mir manchmal das Herz gebrochen. Eure Lie-
be war meine wichtigste Stütze, die mir geholfen hat, diese Arbeit abzuschlie-
ßen. Ich freue mich riesig auf unser Familienleben zu viert und auf die Abend-
teuer die noch auf uns warten.   
An dieser Stelle möchte ich auch an einen sehr guten Freund erinnern, der viel 
zu früh von uns gegangen ist: Dr. Alexander Riechers. Ich kann es immer 
noch nicht fassen, dass du nicht mehr unter uns bist. Mir fehlen dein Lachen, 
deine immer fröhliche Art und die Gummibärchen, die du immer für alle bereit 
hattest. Wie gerne hätte ich diesen Moment mit dir geteilt und mit dir gefeiert. 
 VII 
 
Mit deiner unbändige Hilfsbereitschaft, deinem immensen Wissen und deiner 
liebe zur Wissenschaft, warst du immer ein Vorbild für mich. Alex, du fehlst mir!  
 
 
1. Table of contents VIII 
 
1. Table of contents 
1. Table of contents .................................................................................... VIII 
2. Abbreviations and Acronyms .................................................................... XI 
3. Motivation................................................................................................. 16 
4. Background .............................................................................................. 20 
4.1 Metabolomics .............................................................................. 20 
4.1.1 Fingerprinting analysis .................................................... 20 
4.1.2 Profiling analysis ............................................................. 22 
4.2 LC-MS based metabolomics in the study of chronic kidney disease
 .................................................................................................... 23 
4.3 Data analysis of untargeted large scale metabolomic studies ..... 28 
4.3.1 Data processing .............................................................. 29 
4.3.2 Data visualization and statistical analysis ....................... 30 
4.4 Identification of metabolites by LC-MS analysis .......................... 32 
4.4.1 Identification workflow ..................................................... 33 
4.4.2 Concrete examples for LC-MS based identification ........ 36 
5. Experimental section ................................................................................ 39 
5.1 Materials ...................................................................................... 39 
5.2 Sample preparation ..................................................................... 39 
5.3 Instrumentation............................................................................ 39 
5.3.1 HPLC-ESI-TOFMS ......................................................... 39 
5.3.2 HPLC-ESI-QqQMS ......................................................... 40 
5.3.3 Miscellaneous ................................................................. 41 
5.4 Data analysis ............................................................................... 41 
5.4.1 Software ......................................................................... 41 
5.4.2 Calibration curves ........................................................... 42 
5.4.3 Retention time corrector (RTcorrector) ........................... 42 
5.4.4 Bucket assigner .............................................................. 43 
5.5 Validation methods ...................................................................... 44 
5.5.1 Hierarchical cluster analysis ........................................... 44 
5.5.2 Bland-Altman plot ........................................................... 45 
6. Evaluation of dilution and normalization strategies to correct for urinary 
output in HPLC-HRTOFMS metabolomics ............................................... 46 
6.1 Introduction ................................................................................. 46 
6.2 Materials and Methods ................................................................ 48 
6.2.1 Chemicals. ...................................................................... 48 
6.2.2 Urine specimens ............................................................. 48 
6.2.3 Sample preparation ........................................................ 49 
1. Table of contents IX 
 
6.2.4 Creatinine quantification ................................................. 50 
6.2.5 Osmolality ....................................................................... 51 
6.2.6 LC-MS Analysis .............................................................. 51 
6.2.7 Data Analysis .................................................................. 52 
6.3 Results and Discussion ............................................................... 54 
6.3.1 Creatinine Quantification ................................................ 54 
6.3.2 Basic characteristics of the first sample set .................... 54 
6.3.3 Effects of different dilution strategies on missing values . 57 
6.3.4 Evaluation of different dilution strategies and normalization 
methods .......................................................................... 59 
6.3.5 Classification of a second sample set ............................. 66 
6.3.6 Feature identification ...................................................... 67 
6.3.7 Analysis of an independent patient cohort ...................... 68 
6.4 Conclusions ................................................................................. 72 
7. Development of a quantitative LC-QqQMS method for renal disease-
associated metabolites ............................................................................ 73 
7.1 Introduction ................................................................................. 73 
7.2 Experimentals ............................................................................. 74 
7.2.1 Chemicals ....................................................................... 74 
7.2.2. Solutions ......................................................................... 75 
7.2.3 Sample preparation ........................................................ 77 
7.2.4 Instrumentation ............................................................... 78 
7.3 Method validation ........................................................................ 80 
7.3.1 Quantification .................................................................. 80 
7.3.2 Linear range, LOD and LOQ ........................................... 81 
7.3.3 Recovery and precision .................................................. 81 
7.4 Results and Discussion ............................................................... 82 
7.4.1 Chromatographic separation and MS detection of analytes
 ....................................................................................... 82 
7.4.2 Calibration ...................................................................... 85 
7.4.3 Spiking experiment ......................................................... 88 
7.4.4 Application ...................................................................... 90 
7.5  Conclusions ................................................................................. 94 
8. Comparison of fingerprinting LC-HRTOF-MS and LC-QqQMS profiling 
data .......................................................................................................... 96 
8.1 Introduction ................................................................................. 96 
8.2 Materials and Methods ................................................................ 99 
8.2.1 Calibration curves and urine sample preparation ........... 99 
8.2.2 Instrumentation ............................................................. 100 
8.2.3 Data analysis ................................................................ 100 
8.3 Results and Discussion ............................................................. 101 
8.3.1 Comparison of calibration curves ................................. 101 
1. Table of contents X 
 
8.3.2 Comparison of population based measurements on 
targeted and untargeted platforms ................................ 104 
8.4 Conclusions ............................................................................... 110 
9.  Conclusion and Perspectives ................................................................ 112 
10. References ............................................................................................. 114 
11.  Appendix ............................................................................................... 122 
12. Publications and Presentations .............................................................. 126 
12.1 Publications ............................................................................... 126 
12.2 Book Chapter ............................................................................ 127 
12.3 Oral Presentation ...................................................................... 127 
12.4 Poster Presentation ................................................................... 127 
13. Summary................................................................................................ 128 
14. Zusammenfassung ................................................................................ 131 
 
 
2. Abbreviations and Acronyms XI 
 
2. Abbreviations and Acronyms 
 
AA Anthranilic acid 
 
AER Albumin excretion rate 
 
AKI Acute chronic kidney injury 
 
CKD Chronic kidney disease 
 
CMT C-Mannosyltryptophan 
 
CRE Creatinine 
 
CRT Creatine 
 
Da  Dalton 
 
DMX Dimethylxanthine 
 
DN Diabetic nephropathy 
 
eGFR Estimated glomerular filtration rate 
 
eGFRcr Estimated GFR based on creatinine 
 
ESI Electrospray ionization 
 
ESRD End stage renal disease 
 
FDA Food and Drug Administration 
 
GC Gas chromatography 
 
GFR Glomerular filtration rate 
 
GUA Guanidinoacetate 
 
HAA Hydroxyanthranilic acid 
 
HIAA Hydroxyindolacetic acid 
 
HIP Hippuric acid 
 
HK Hydroxykynurenine 
 
2. Abbreviations and Acronyms XII 
 
HMDB Human Metabolome Database 
 
HPLC High performance liquide chromatography 
 
HRTOF High-resolution time-of-flight 
 
HX Hypoxanthine 
 
IAA Indole-3-acetic acid 
 
IDA Isotope dilution analysis 
 
ILA Indole-3-lactic acid 
 
INC Indole-3-carboxaldehyde 
 
IPA Indole-3-propionic acid 
 
IS  Internal standard 
 
IS 3-Indoxylsulfate 
 
KA Kynurenic acid 
 
KYN Kynurenine 
 
LC Liquid chromatography 
 
LLOQ Lower limit of quantification 
 
LOD Limit of detection 
 
LOQ  Limit of quantification 
 
m/z Mass-to-charge ratio 
 
MEL Melatonin 
 
MG Methylguanine 
 
MI 1-Methylinosine 
 
MRM Multiple reaction monitoring 
 
MS Mass spectrometry 
 
MS/MS  Tandem mass spectrometry 
 
MX Methylxanthine 
 
NA Nicotinic acid 
2. Abbreviations and Acronyms XIII 
 
NAM Nicotinamide 
 
NIST National Institute of Standards and Technology  
 
NMR Nuclear magnetic resonance 
 
PCA Principle component analysis 
 
PLS-DA Partial least squares discriminant analysis 
 
PSU Pseudouridine 
 
QA Quinolinic acid 
 
qMS Quadrupole mass spectrometry 
 
QqQ-MS Triple quadrupole MS 
 
qTOF Quadrupole-Time-of-flight hybrid mass spectrometry 
 
RSD Relative standard deviation 
 
S/N Signal to noise ratio 
 
SER Serotonin 
 
SIL-IS Stable isotope labeled internal standard 
 
SVM Support vector machines 
 
TG Tiglylcarnitine 
 
TIC Total ion current 
 
TOF Time of flight 
 
TPO Tryptophol 
 
TRP Tryptophan 
 
TRY Tryptamine 
 
UA Uric acid 
 
ULOQ Upper Limit of quantification 
 
XA Xanthurenic acid 
 
XIC Extracted ion chromatogram 
 
XT Xanthine 
 XIV 
 
 
 
 
3. Motivation 16 
 
3. Motivation 
Metabolomics aims at the holistic analysis of the qualitative and quantitative 
composition of low molecular weight compounds in biological systems.1 The 
major goal is the determination of metabolites, quantitatively as well as qualita-
tively, that differ between biological groups. This information is contributing to 
the understanding of the underlying biological mechanisms under investigation. 
A common matrix for large scale metabolomics studies is urine since it is ob-
tained non-invasively.2,3 However, urinary output can vary widely due to various 
processes involved in the body’s water balance. The hydration is influenced by 
water uptake, loss of water due to respiration, perspiration and defecation3. As a 
result, variable urine amounts are excreted, which effects the metabolite con-
centrations measured in the urine. Hence, untargeted LC-MS based metabo-
lomics analyses of urine samples are challenging due to these biological vari-
ances that are not necessarily related to the phenotype under investigation. 
Consequently, to reveal the true biological variances, normalization strategies 
are necessary.4 Commonly, creatinine is utilized to normalize for urinary output. 
Creatinine is an endogenous metabolite, produced at a constant rate and main-
ly excreted by glomerular filtration.5 However, creatinine concentration can vary 
widely due to various factors, such as age, sex, body mass, health, diet or water 
intake.4 Alternatively, the osmolality, which is the molar sum of all solutes in 
urine, can be applied for correcting the urinary output because it reflects the 
urinary output more closely.4 6 The common normalization procedure in metabo-
lomics encompasses a uniform dilution of urine samples followed by a post-
acquisition normalization to either creatinine concentration or to the sum of all 
integrals of each sample. Nevertheless, these normalization methods are una-
ble to correct for column overloading, peak overlapping or ion suppression. Fur-
thermore, a uniform dilution may result in failure to detect analytes in urine 
specimens of low concentration. Therefore, a normalization strategy is needed 
to overcome these shortcomings.  
Chronic kidney disease (CKD) is a major public health concern affecting more 
than 10% of the population worldwide.7 Serum creatinine is the most commonly 
used clinical biomarker of renal dysfunction. However, there are important limi-
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tations to its use. For example, it rises only after 50% of kidney function is al-
ready lost. Additionally, tubular secretion of creatinine results in overestimation 
of renal function at lower glomerular filtration rates (GFR) and, as already men-
tioned above, it reflects differences in muscle mass.8 Hence, serum creatinine 
concentrations can vary widely. Therefore, the estimation of GFR can be inac-
curate. Cystatin C has been proposed as an alternative and more sensitive 
marker of eGFR.9,10 However, it is metabolized by proximal tubular cells.11 The 
ideal filtration markers for GFR estimation should exhibit no or only little net re-
absorption or secretion in the nephron. This leads to the clinical necessity of 
additional markers for an early detection of CKD. Additionally, the underlying 
pathophysiological mechanisms are still not fully understood.12 Sekula et al. 
found that C-mannosyltryptophan and pseudouridine were strongly and repro-
ducibly associated with eGRF and CKD in population-based studies.12 There-
fore, a quantitative method for further investigations was required for these me-
tabolites.  
For quantification of small molecules and metabolites, the triple quadrupole 
mass spectrometer in multiple reaction monitoring (MRM) mode has been the 
golden standard. However, with recent developments regarding the mass accu-
racy, resolution and scan times, the relative quantification with a quadrupole 
Time-of-flight-mass spectrometer (qTOF-MS) in full scan mode is possible.13 
Nevertheless, very little is known about the performance of quantification in full 
scan mode, also called untargeted screening, in biological matrices. Lu et al. 
compared the performance of a triple quadrupole instrument in MRM mode to a 
TOF-MS in full scan mode for the analysis of 20 standard compounds (10 in 
positive ion mode, 10 in negative ion mode) at 5 different concentration levels 
and a cellular extract.13 However, they only showed the results for one standard 
compound. Therefore, a comparison of the absolute quantification via MRM 
mode and relative quantification via qTOF-MS in full scan mode in urine is 
needed.  
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Aim#1: Evaluation of strategies to reduce sources of variance in untarget-
ed LC-MS based metabolomic analysis  
As the sample preparation is one of the first steps in the analytical process, the 
first goal of this thesis was the optimization of the sample preparation of urine to 
correct for urinary output. For this purpose, the performance of different pre- 
and post-acquisition normalization methods to correct for urinary output in LC-
MS based metabolic fingerprinting was systematically compared. As pre-
acquisition methods, sample dilution to either a uniform creatinine concentra-
tion, osmolality value, or using a constant factor were used. For the different 
post-acquisition normalization methods such as normalization to creatinine, os-
molality and sum of all integrals, data were acquired with a constant 1:4 dilution. 
Urine specimens from patients with chronic kidney disease from two different 
epidemiological studies, namely the German chronic kidney disease study 
(GCKD)14 and the Trial to reduce cardiovascular events with Aranesp therapy 
(TREAT)15 study and healthy controls were chosen for evaluation of the differ-
ent normalization and dilution strategies. 
 
Aim#2: Development of a quantitative LC-QqQMS profiling method 
The aim was the development of a sensitive and reliable quantitative profiling 
method for metabolites recently associated with renal disease, e.g. pseudouri-
dine and C-mannosyltryptophan in order to further investigate these metabolites 
as potential markers. Moreover, seven metabolites identified as discriminating 
metabolites between patients suffering from CKD and healthy controls within 
the evaluation of normalization strategies together with the metabolites of the 
tryptophan pathway were also implemented in this method for further investiga-
tions. The validated method was applied for the quantification of 383 urine and 
plasma samples from the GCKD study to analyze the fractional excretion.  
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Aim#3: Comparison of untargeted screening LC-qTOFMS and quantitative 
LC-QqQMS analysis  
The goal was the comparison of fingerprinting LC-qTOFMS data and quantita-
tive LC-QqQMS data of urine samples from the GCKD study. Since, the kidney 
function has a broad impact on circulation metabolite levels, untargeted 
metabolomics is a promising approach in nephrology research. However, the 
major drawback of untargeted (full scan) MS-based metabolomics is the semi-
quantitative nature of the data.16 They are in arbitrary units and therefore cannot 
be compared across studies and further investigations e.g. in different matrices 
are difficult.17 In contrast, metabolic profiling methods provide absolute concen-
trations for the investigated metabolites. Therefore, the generated data from the 
two different approaches were compared via Bland-Altman plots for a defined 
set of metabolites. Moreover, the lower limit of quantification (LLOQ), the upper 
limit of quantification (ULOQ), the linear range as well as the relative standard 
deviation (RSD) of the standard compounds for different concentrations were 
calculated and compared for both approaches.  
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4. Background 
This chapter is focusing primarily on untargeted LC-MS based metabolomics.  
4.1 Metabolomics 
Metabolomics aims to investigate, qualitatively as well as quantitatively, all me-
tabolites in a biological system simultaneously. Metabolites are low molecular 
weight compounds (<1000 Da) of organic or inorganic origin, which comprise 
mainly educts, intermediates or products of enzymatic biochemical reactions.18 
Metabolomics encompasses the study of discriminative changes in metabolite 
profiles due to genetic modifications, physiological stimuli, environmental, nutri-
tional or other factors 18. Hereby, the ultimate goal is the recognition of discrimi-
native pattern rather than identifying all detected compounds.19  
4.1.1 Fingerprinting analysis 
Untargeted metabolomics, also called fingerprinting analysis, is considered to 
be the true “omics” approach.20 Fingerprinting analysis enables a global snap-
shot of the metabolic phenotype and therefore is also a valuable diagnostic tool. 
19,21,22 The metabolome is the end-stage of the “omics”-cascade and hence re-
flects genetic, disease, life style, as well as environmental responses. Metabolic 
profiles, obtained by analyzing metabolites, for instance, in body fluids such as 
serum or urine, provide additional information that cannot be obtained by inves-
tigating the genotype, transcriptome, or even proteome. This additional 
knowledge can contribute to the achievement of personalized drug therapy.22 
The analysis of reflective metabolite pattern enables therapy on a more person-
alized level. Besides genotype variations, environmental influences like diet, 
which individually influence drug metabolism or toxicity, are also taken into ac-
count.23 Moreover, the characterization of metabolic networks by multiparamet-
ric analysis may enable earlier diagnoses of some diseases.24 
 As a large scale procedure, fingerprinting analysis covers a wide range of me-
tabolites and enables a high number of experiments in a relatively short 
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time.20,21 However, the varying molecular weight, hydrophobicity/hydrophilicity, 
acidity/basicity and boiling points of the metabolites represent major technical 
challenges. Technical platforms need to fulfill a variety of requirements like high 
accuracy, sensitivity and reproducibility.20 Primarily, two different platforms are 
employed, which are either based on mass spectrometry (MS), coupled to a 
separation technique, or nuclear magnetic resonance (NMR). In principle, gas-
chromatography-mass-spectrometry (GC-MS) and liquid-chromatography-
mass-spectrometry (LC-MS) are the mainly used MS based platforms. Mass 
spectrometry based approaches have the potential not only to quantify metabo-
lites with high sensitivity and selectivity but also to identify them. However, 
sample preparation is a crucial step for MS based analyzing techniques. Sam-
ple preparation should be as simple as possible to minimize the loss of ana-
lytes. Therefore, sample matrices that are compatible with the analytical tech-
nique, are commonly only diluted and the dilution is adapted with respective to 
the sample concentration and the dynamic range of the MS. The coupling to a 
chromatographic separation technique reduces complexity of the matrix by add-
ing the time scale as a further dimension. Moreover, it enables an isobaric sep-
aration and achieves additional physicochemical information of the compounds.  
Since GC-MS with electron ionization (EI) is a well-established method in 
metabolomics, robust protocols are available for fingerprinting analysis including 
maintenance, sample preparation, chromatographic evaluation and identifica-
tion.21 The highly reproducible fragmentation with EI enables the implementa-
tion of mass spectral libraries which facilitates metabolite identification. Never-
theless, GC-MS is restricted to volatile analytes although chemical derivatiza-
tion increases the range of detectable metabolites. Derivatization is a major bot-
tleneck of GC-MS analysis because it can lead to different forms of derivatives 
for the same analyte, the derivatization reaction can be incomplete or it can lead 
to byproducts or degradation.25 Furthermore, the additional sample preparation 
step may increase the analytical variance and can cause the loss of metabo-
lites. However, there are correction methods, e.g. the derivatization of standard 
compounds and normalization methods, to overcome these shortcomings.25 
Nevertheless, GC-MS is considered to be the golden standard in metabolomics.  
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Yet, LC-MS has recently enjoyed a growing popularity as platform in metabo-
lomics fingerprinting studies mostly because it can be applied to a larger diversi-
ty of molecules21,26,27. Moreover, there is no need for a derivatization step, 
which simplifies the sample preparation. The lower analysis temperatures allow 
a gentler metabolite handling.28 However, metabolite identification is more diffi-
cult due to the lack of comprehensive databases. Additionally, LC-MS meas-
urements of complex matrices are hampered by ion suppression. The simulta-
neous presence of multiple metabolites affects the ionization, which impedes 
quantification of these metabolites. Despite these difficulties recent enhance-
ments in separation, ionization and mass accuracy, have contributed to a new 
level of performance. These new achievements made LC-MS a complimentary 
gold standard in metabolomics.  
For the analysis of fingerprinting metabolomics data, the whole e.g. LC-MS 
chromatogram is exported. These signals yield characteristic patterns for each 
sample which can be tested for significantly different signals of different groups 
or can be used to classify the samples (see chapter 4.3). The significantly dis-
criminating signals, also called features or markers, are then further investigat-
ed and identified (see chapter 4.4.). Therefore, data complexity is reduced and 
only discriminatory metabolites are further analyzed and biologically interpreted.  
Alternatively, NMR is applied as a comprehensive platform for fingerprinting 
analysis. Despite limitations in sensitivity, NMR provides a rapid, non-
destructive, high throughput analysis with minimal sample preparation efforts.28 
Nevertheless, spectra are complex because most metabolites result in multiple 
signals that often overlap with signals from other metabolites. Therefore, me-
tabolite identification is more complicated than with MS based approaches. 
Moreover, a relatively large sample amount of a few hundred microliters is re-
quired for NMR analysis. Due to the often restricted sample amount this is a 
major disadvantage of the NMR approach.  
4.1.2 Profiling analysis 
The second approach in metabolomics is called profiling or targeted analysis. 
Thereby, defined sets of metabolites of a specific compound class or pathway 
are investigated quantitatively. For this purpose, analytical methods are special-
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ly tailored to the respective metabolite set to be quantified. Moreover, sample 
preparation is normally more extensive than for fingerprinting analysis in order 
to minimize sample complexity prior to the measurements or to achieve a sam-
ple pre-concentration for low abundant metabolites. Reference compounds with 
a known amount and an appropriate assortment of internal standards (IS) are 
applied to establish calibration curves for the quantification of the target ana-
lytes. Instead of calibration curves, isotope dilution analysis (IDA) is also utilized 
for quantification (see Figure 4.1). Therefore, a known amount of the stable iso-
tope labeled internal standard (SIL-IS) is added to the analyte to be quantified 
before the sample preparation procedure.29 Hence, the losses of the analyte 
and SIL-IS are proportional and both are affected equally by ion suppression, 
matrix effects, injection variability and signal drifts. For the quantification the 
ratio of the peak area of the analyte to the SIL-IS is multiplied by the concentra-
tion of the SIL-IS.29 However, IDA is not only suited for quantification within a 
profiling analysis but it is also applicable for fingerprinting analysis (see chapter 
6).  
  
Figure 4.1: Isotope dilution analysis (IDA) exemplarily shown for the quantification of creatinine 
applying stable isotope labeled D3-creatinine. Adapted by permission from Springer, Practical 
Gas chromatography by Katja Dettmer-Wilde and Werner Engewald, Springer-Verlag Berlin 
Heidelberg 2014.
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4.2 LC-MS based metabolomics in the study of chronic 
kidney disease    
The kidneys play an important role in the acid-base balance, the regulation of 
plasma volume and hormone secretion, which all maintain vertebrate homeo-
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stasis.30 However, many kidney diseases can hamper these processes. Kidney 
diseases which persist over 3 months or longer are considered to be chronic 
(chronic kidney disease, CKD).31 Approximately 8-10% of the western popula-
tion is affected by CKD.32 The clinical picture of CKD shows a progressive loss 
of the kidneys ability to filter potentially toxic compounds out of the blood into 
the urine.33 Consequently, toxic compounds accumulate in the body, negatively 
affecting biological functions. Such compounds are also called uremic 
toxins.33,34 Ninety uremic retention solutes were classified accordingly following 
the suggestion of the European uremic toxin work group.33,35 This list was ex-
tended in 2012 by Duration et al. who assigned 56 additional uremic toxins.35  
Diabetes mellitus and high blood pressure are the most prominent causes of 
CKD.36 Patients suffering from diabetic mellitus are at increased risk of develop-
ing diabetic nephropathy (DN). 30-40% of type 1 and 15-20% of type 2 diabetes 
mellitus patients have DN after 20 years. 37,38 
CKD is classified into five stages according to its severity. The classification is 
based on the estimated glomerular filtration rate (eGFR). The GFR is defined as 
the volume of plasma filtered by the glomeruli per unit of time.39 It is equal to the 
Clearance Rate if the filtered substance is freely filtered and neither reabsorbed 
nor secreted by the kidney. Therefore, it can be measured using the clearance 
of filtration markers such as urinary creatinine. Urinary clearance can be calcu-
lated applying the formula CL = U x V / P,40,41 where U represents the urinary 
concentration, V the urinary flow rate, and P the plasma concentration.40 GFR 
can also be estimated from serum levels of endogenous filtration markers 
(eGFR), such as serum creatinine or cystatin C, without the need of calculating 
the clearance.40 A variety of different estimating equations are available using 
creatinine, all of them come with variable biases across populations and are 
imprecise.40  Several estimation equations using cystatin C have also been pub-
lished.40 Calculation of eGFR based on cystatin C is not affected by muscle 
mass and diet. Hence, it is more reliable than calculations based on creatinine 
and not as strongly associated by sex, age and race.40 On the downside, there 
is some evidence that shows cystatin C levels are influenced by tubular excre-
tion.40  Additionally, a combination of creatinine and cystatin C can also be used 
for the calculation of the eGFR.  
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Stage one of the CKD classification, as the mildest CKD class, shows only few 
symptoms (e.g. proteinuria) with a GFR < 90 mL/min/1.73 m2, while stage five 
as the end stage displays severe symptoms (e.g. kidney failure) with a poor life 
expectancy if untreated (GFR < 15 mL/min/1.73 m2).33 End stage renal disease 
(ESRD) either requires dialysis or renal replacement. In many kidney diseases, 
kidney damage can also be determined by albuminuria which is diagnosed 
based on urinary albumin excretion rate (AER).31,42 
Kidney disease and its associated metabolites were investigated with markedly 
‘low-tech’ methodologies by physicians since the Middle Ages.43 At that time, 
color, smell and taste of urine were applied to diagnose and specify renal dis-
ease. Nowadays, clinical markers such as serum creatinine have been estab-
lished for the detection of CKD. 43 While classical assays, like colorimetric (Jaffe 
reaction) or enzymatic assays,40 are still the gold standard in routine diagnos-
tics, rapid  improvements in analytical techniques made especially LC-MS a 
popular tool in the search for clinical markers. However, the sensitivity of these 
markers (e.g. creatinine), only allows the detection of CKD at later stages (see 
also chapters 6 and 7), leaving the urgent need for the identification of early 
detection markers. Aside from early detection, identification of those patients at 
increased risk of progressing rapidly to ESRD is a pressing issue. 
In the following, studies using untargeted LC-MS metabolomics for the identifi-
cation of CKD-biomarkers in human urine, serum and plasma specimens are 
summarized. In short, untargeted LC-MS has proved to be a very useful tool for 
the identification of potential novel clinical markers for CKD due to its holistic 
analysis character. However, the analytical methods and the statistical analysis 
of the acquired data are critical aspects that need to be addressed in order to 
achieve valid results (see chapter 6).  
In 2015, Sekula et al. used untargeted LC- and GC-MS to investigate human 
serum specimens of three different cohorts within the general population of the 
KORA F4 study, the TwinsUK registry and the AASK study.34 They quantified 
493 small metabolites in human serum samples. Moreover, they analyzed the 
correlation between these molecules and the GFR estimated on the basis of 
creatinine (eGFRcr) and cystatin C levels of participants in the KORA F4 study 
and the TwinsUK registry. The statistical analysis yielded 54 metabolites that 
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were significantly associated with eGFRcr. They also found that C-
mannosyltryptophan, pseudouridine, N-acetylalanine, erythronate, myo-inositol, 
and N-acetylcarnosine show a pairwise correlation (r≥0.50) with routine kidney 
function measures.34 Moreover, they demonstrated that higher C-
mannosyltryptophan, pseudouridine, and O-sulfo-L-tyrosine concentrations are 
related to incident CKD (eGFRcr <60 ml/min per 1.73 m2) in the KORA F4 
study. Additionally, they demonstrated that C-mannosyltryptophan and pseu-
douridine correlated (0.78) with measured GFR of patients of the AASK study. 
Adjusting both metabolites to measured GFR resulted in the disappearance of 
the highly significant relation to ESRD. In summary, Sekula et al. were able to 
demonstrate that both metabolites could be alternatively used to determine kid-
ney function. However, this study was based on semi-quantitative data. Thus, 
they needed to verify these findings and specify reference ranges by quantita-
tive data. In order to overcome this shortcoming, in the course of this thesis se-
rum and urine samples from the GCKD study were quantitatively investigated 
by LC-QqQ-MS which contributed to the study published by Sekula et al in 
2017.44 In this study, the novel kidney function markers C-mannosyltryptophan 
and pseudouridine were characterized in blood and urine specimens of subjects 
with and without CKD. Additionally, fractional excretions and the relation to GFR 
were determined and quantitative and semi-quantitative data were compared.  
Boelart et al. 2014 investigated blood serum specimens from 20 patients each 
with CKD stage 3 and hemodialysis requiring stage 5, and a healthy control 
group (N=20), by means of high-resolution LC-qTOF-MS and GC-qMS in posi-
tive and negative ionization mode.33 This study put emphasis on the validity of 
the applied method. They used quality control samples and demonstrated 
method validity by satisfactory retention time shifts, mass accuracy and peak 
area fluctuations. In order to identify significantly discriminating metabolites be-
tween the investigated groups, the Mann-Whitney unpaired test (Benjamini–
Hochberg FDR corrected) was applied. They were able to identify 85 metabo-
lites associated with advanced CKD.33 Aside from 43 metabolites that had been 
already reported earlier, 31 unique metabolites were identified, whose serum 
levels increased significantly with CKD progression, while the serum levels of 
11 additional metabolites decreased with CKD progression. Eighteen novel me-
tabolites were identified in positive ionization mode, including acetylhomoserine, 
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methylglutarylcarnitine, 3-methyluridine/ribothymidine, methyluric acid, nico-
tinuric acid/isonicotinylglycine, oxoprolylproline and the dipeptide PhePhe. 33 
Plasma samples from 30 non-diabetic men with different CDK stages were in-
vestigated applying LC-LTQ-MS and GC-MS by Shah et al. in 2013.45 Metabo-
lite profiles of CKD stages 2, 3 and 4 (each N= 10) were compared to identify 
novel biomarkers for the respective CKD stage.45 CKD stages were determined 
based on the eGFR. Different sample groups were examined on the basis of 
Welch’s t-test corrected for multiple testing by the FDR and random forest clas-
sification. Statistical analysis yielded 62 significant different metabolites be-
tween stage 3 and 2, 111 metabolites between stages 4 and 2 and 11 metabo-
lites between stage 4 and 3. Within this study major metabolic differences were 
revealed, reflecting inter alia alterations in arginine metabolism.45 
Untargeted LC-ESI-TOF-MS was applied in the study of Sato et al. in 2011 to 
investigate plasma specimens from patients with end-stage renal disease 
(ESRD), who were treated with hemodialysis (N=10).46 As a control group, 
samples from healthy subjects (N=16) were used. The investigation of the 
plasma samples before and after hemodialysis yielded 54 metabolites whose 
concentrations were affected by hemodialysis. Significant differences were de-
termined utilizing analysis of variance (ANOVA). The Tukey–Kramer’s multiple 
comparison test for pairwise comparisons was applied for further analysis. Ac-
cording to the authors, the discovery of methylinosine and two unknown mole-
cules with an m/z ratio of 257.1033 and 413.1359 as potential biomarkers could 
be helpful to identify the appropriate hemodialysis dose. However, these poten-
tial biomarkers need to be confirmed.46  
Untargeted LC-qTOF-MS was also used in the study of Jia et al. in 2008.47 The 
authors examined serum samples from 32 patients with chronic renal failure 
without renal replacement therapy and 30 healthy volunteers. They intended to 
discover novel biomarkers and shed light on their pathophysiological changes. 
Statistical analysis revealed 7 potential biomarkers: creatinine, tryptophan, phe-
nylalanine, kynurenine and three lysophosphatidylcholines. This study empha-
sized the importance of untargeted LC-MS metabolomics and its future in clini-
cal diagnostics.47  
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LC-MS was also exploited to reveal early biomarkers for DKD.42 In order to dif-
ferentiate progressive albuminuria from non-progressive albuminuria, the au-
thors used urine specimens from patients suffering from type 1 diabetes with a 
normal urinary albumin excretion rate. After 5.5 years of follow-up, half of the 
patients had progressed from normoalbuminuria to microalbuminuria whereby 
the other half had remained normoalbuminuric.42 They employed both LC-LTQ-
FT-MS and GC-MS. Multivariate logistic regression analysis yielded a profile of 
metabolites that discriminated patients with deteriorating albumin excretion rate 
(microalbuminuric) from normoalbuminuric patients with an accuracy of 75% 
and a precision of 73%. The discriminating profile included acyl-carnitines, acyl-
glycines and metabolites linked to the tryptophan metabolism. Moreover, the 
discriminating profile included metabolites already linked to DKD.42  
In 2009, Zhang et al. focused on the metabolic research of diabetic nephropathy 
and type 2 diabetes mellitus.37 An UPLC-TOF-MS system was utilized to differ-
entiate global serum profiles of 8 patients suffering from diabetic nephropathy 
(DN), 33 type 2 diabetes mellitus (T2DM) patients and 25 healthy volunteers.37 
Moreover, the authors intended to identify potential biomarkers for DN. Principle 
component analysis was implemented for group separation. Distinctive clusters 
between patients and healthy volunteers were observed. Further, DN and 
T2DM patients were separated in the scores plot. An independent t-test yielded 
8 metabolites significantly differentiating patients and controls. However, they 
only tentatively identified 3 of these metabolites: leucine, dihydrosphingosine 
and phytosphingosine.37  
4.3 Data analysis of untargeted large scale metabolomic 
studies 
Data analysis of untargeted LC-MS data encompasses several steps including 
data pre-processing, statistical analysis, identification of metabolites, validation 
of the results followed by biological classification and interpretation. Untargeted 
LC-qTOF-MS measurements of large scale metabolomic studies generate high-
ly complex data. Commonly data are generated over several months or years 
and sample sets comprise hundreds to thousands of samples. Therefore, data 
variability originates not only from biological variance but also from technical 
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variance and batch effects. Resulting issues that need to be addressed are e.g., 
retention time (RT) shifts, peak alignment and missing values, just to name a 
few. Hence, a special focus must be placed on data processing and analysis to 
obtain solid and robust data for statistical and biological interpretation. Here, the 
basic concepts of data processing and analysis are covered as they were ap-
plied throughout this thesis. Moreover, recommendations for the instrumental 
analysis to avoid batch- and technical effects are described.  
4.3.1 Data processing  
Data processing starts with the recalibration of the mass scale (see chapters 
4.4.1 and 5.3.1). Then, a peak picking algorithm searches automatically for 
peaks in the chromatographic trace. Bruker Daltonics Find Molecular Feature 
algorithm (Bremen, Germany) searches for ions that belong to one compound 
(peak). The search is based on a high correlation in time and m/z distances 
(e.g. isotopic distances) of these ions. The resulting compound is therefore the 
average of these clustered ions. Afterwards, peaks across the chromatograms 
of different samples are aligned in a single matrix. In the data matrix, which is 
also called bucket table, every peak is represented by its m/z value, retention 
time and area integral.  
However, as already mentioned, in large scale metabolomics studies pitfalls like 
RT shifts occur which affect peak alignment and may increase the number of 
missing values. RT shifts can result in the alignment of wrong peaks throughout 
the samples and batches. Moreover, peaks found in some samples may not be 
found in other samples of the same or different batches resulting in missing val-
ues in the bucket table. In that case, it is difficult to distinguish between “true” 
missing values, because the signal was below the limit of detection, and peaks 
missed due to retention time shifts or incorrect alignment. Identifying the origin 
of a missing value would require the manual inspection of all signals, which is 
not feasible in the case of thousands of features detected. However, missing 
values constitute a serious problem in statistical data analysis (see chapter 6).  
Accordingly, measurements must be performed with great care (see chapter 
4.3.3). For severe (between-) batch effects we developed a correction strategy 
for retention time shifts to reduce missing values. Each batch is aligned sepa-
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rately by the commercially available software which was in our case the Bruker 
Daltonics ProfileAnalysis software. Additionally, we developed a tool for correct-
ing RT shifts according to one or more prominent compounds in the sample ma-
trix. Differences in retention time for these house-keeping compounds are used 
to correct those of the remaining compounds (see chapter 5.4.3). Afterwards, 
with subsequent pairwise bucketing via an in-house written bucket assigner all 
the measured batches are combined (see chapter 5.4.4). The described proce-
dure was applied in chapter 8. The Bucket assigner alone was also implement-
ed in chapter 6. This procedure reduces missing values. Nevertheless, some 
missing values still remain in the data matrix because they are either true miss-
ing values or the detected area is below the signal-to-noise threshold. Conse-
quently, this requires imputation of the missing values prior to statistical analy-
sis. Therefore, 1/10th of the minimal detected area integral can be inserted. Al-
ternatively, methods like missing completely at random or k-nearest neighbor 
imputation method (knn) can be utilized.48,49 Moreover, prior to multivariate data 
analysis, it is necessary to reduce any variance in the data which is not biologi-
cally induced. Strategies to avoid batch effects and technical variations in ad-
vance are described in chapter 4.3.3. Different normalization methods were 
tested in this thesis to reduce any contribution from unwanted biases and exper-
imental variance before and after the measurement of the urine samples (for 
details see chapter 6). However, normalization to the sum of all buckets can be 
utilized independent of the sample origin.  
4.3.2 Data visualization and statistical analysis 
Statistical analysis approaches applied for high throughput data like LC-MS da-
ta are mainly adapted from earlier developed omic technologies.50. Commonly, 
univariate or multivariate approaches are used in order to search for group sep-
aration. Classical univariate analysis are the two-sided t-test or the analysis of 
variance (ANOVA) followed by a post-hoc test. Especially for large scale 
metabolomics where thousands of features are detected, it is important to cor-
rect for multiple testing. Adjusting for multiple testing by controlling the false dis-
covery rate according to Benjamini and Hochberg51 is an example for such a 
correction. Multivariate analysis methods use not only single discriminating me-
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tabolites but also dependency structures to differentiate sample groups.50 Most 
prominently utilized methods are principle component analysis (PCA), cluster 
analysis and classification methods like the random forest (RF) classifier. As a 
starting point for data analysis, the PCA is a very valuable tool to decrease 
complexity of large scale LC-MS data and to visualize differences between 
samples. Thereby, loading plots can help to identify discriminating metabolites. 
Another popular method in metabolomics data analysis is the partial least 
squares discriminant analysis (PLS-DA).Instead of PCA, it is a supervised dis-
criminant analysis method, which is dependent on class labels.52  In order to 
analyze high-throughput data in more detail, cluster analysis like hierarchical 
clustering is a valuable unsupervised method. For more details see chapter 
5.5.1. The RF classifier is a supervised classification method based on decision 
trees. Therefore, the data set is split in two sets, training and test set.53 Both are 
selected randomly applying resampling with replacement which is also known 
as bootstrapping. As the names intend, the training set is used to develop the 
decision tree and the test set is applied to calculate the classification accuracy. 
53 According to the literature, the RF is a very accurate and robust classification 
method.53 Support vector machine (SVMs) or regularized linear regression are 
alternative machine learning algorithms widely used in metabolomics data anal-
ysis. These algorithms also use training sets to learn rules and form patterns, 
which then can be utilized to analyze new data.54 
 
4.3.3 Handling batch effects and technical variations 
Batch effects, also called between-block effects, occur in large scale studies 
where samples are measured in several batches over an extended time period. 
In order to prevent any kind of batch effects and technical variation, it is advisa-
ble to consider the following experimental setup recommendations. Firstly, the 
samples should be measured in random order. Secondly, the instrument should 
be cleaned and calibrated before every measurement and the column should be 
equilibrated by injecting blanks and/or a standard before analyzing the sample 
sequence. Attention should also be paid to the eluent preparation and usage. It 
should be prepared exactly the same way every time. Blank samples must be 
measured repeatedly throughout the sequence in order to check for sample car-
ry over and contaminations originating from the column. Moreover, quality con-
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trol samples should be regularly interspersed throughout the measurement to 
investigate inter- and intra- batch effects. These QC samples can be used to 
check for batch effects including retention time shifts after the measurement.  
4.4 Identification of metabolites by LC-MS analysis 
As mentioned above, untargeted metabolomics is a retrospective analysis. In 
order to interpret the acquired data biologically, it is necessary to identify at 
least those metabolites that differentiate the biological groups the most. Howev-
er, this is a very challenging and labor-intensive step especially for untargeted 
metabolomics of complex mixtures like urine, which contain exogenous as well 
as endogenous metabolites originating from individual diet, medication, life-style 
and environmental influences.55 Moreover, the available databases (e.g. Human 
Metabolome Database (HMDB)56, Metlin57, Madison Metabolomics Consortium 
Database (MMCD)58, MassBank59, LIPID MAP60) for metabolite identification 
from LC-MS data are limited in their content and a comprehensive database is 
missing.61 Therefore, it is almost impossible to identify all metabolites measured 
by an untargeted analysis. Sumner et al. introduced four levels of metabolite 
identification confidence.62 Metabolites with at least two orthogonal parameters 
e.g. accurate mass and RT identical to an authentic chemical standard meas-
ured under the same analytical conditions are considered to be confidently iden-
tified (level 1).55,62 However, some metabolites and especially stereoisomers are 
very hard to distinguish even by comparison with an authentic chemical stand-
ard.55 This is due to almost identical RT and m/z values particularly in untarget-
ed metabolomics where the analytical methods are needed to be very robust 
and fast. Therefore, these methods are not perfectly optimized.55 In these cas-
es, alternative analytical methods like NMR or GC-EI-MS need to be applied for 
a positive identification. In comparison to confidentially identified compounds, 
putatively identified compounds or classes (level 2 and level 3, respectively) are 
not confirmed by an authentic standard. Instead only one or two parameters are 
utilized to putatively identify metabolites by comparing them to data from librar-
ies or other analytical properties from different laboratories.55,62 In case of LC-
MS measurements, such properties are accurately measured m/z values, RT or 
fragmentation patterns. Comparing the isotopic pattern to in-silico generated 
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pattern provides additional confidence. Level 4 metabolites are unknown com-
pounds, which can nevertheless be differentiated by the chromatogram or mass 
spectra. Moreover, the relative quantification of level 4 metabolites is feasible. 
However, a confident or putative identification is not possible. 55,62  
4.4.1 Identification workflow 
The first step in the identification workflow is the calculation of the elemental 
formula of a certain accurate mass. This leads to a limited number of alterna-
tives for the identification. However, for a reliable identification this number 
needs to be further reduced. Therefore, different filters and approaches are ap-
plied. 
Firstly, the number of possible alternatives for the elemental composition can be 
limited by reducing the mass error. The more accurate the mass the lower is the 
number of possible elemental formulas.63,64 Therefore, the detected masses 
should be internally recalibrated before calculating the elemental formulas. For 
this purpose, a sodium formate cluster injected via a six-port valve before every 
sample run can be utilized. The sodium formate cluster contains representative 
masses across the required mass range (see Fig.4.2 A). After measurement the 
mass spectrum of the sodium formate cluster is used to recalibrate the mass 
scale, improving the mass accuracy of the measured compounds (see Fig.4.2. 
B).  
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Figure 4.2: A sodium formate cluster is applied for external and internal mass calibration of 
HPLC-ESI-qTOF-MS measurements. (A) The mass spectrum of the sodium formate cluster, 
which is infused at the beginning of each sample analysis, is depicted on the left. The corre-
sponding mass list of the recalibration method is shown on the right. (B) The improvement of the 
mass accuracy after recalibration is illustrated for tryptophan exemplarily.  
Secondly, potential elements and adducts should be initially selected before 
calculating the elemental formula of an accurate mass in order to avoid false 
alternatives from including all elements from the periodic table.64 Of course, cer-
tain knowledge about the source of the unknown is necessary. 
Furthermore, tools like SmartFormula from Bruker Daltonics (Bremen, Germa-
ny) calculate the elemental composition from accurate masses by considering 
the rings-plus-double-bonds equivalent (RDBE), the nitrogen rule, the isotopic 
pattern as well as heuristic and chemical rules as introduced by Kind and Fiehn 
in 2007.65 Consequently, these tools further constrain the composition of ele-
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mental formulas fitting an accurate mass. The RDBE is calculated by the follow-
ing formula: 
𝑅𝐷𝐵𝐸 = 𝑁𝐶 + 𝑁𝑆𝑖 −  
1
2
 (𝑁𝐻 + 𝑁𝐹 + 𝑁𝐶𝑙 + 𝑁𝐵𝑟 + 𝑁𝐼) + 
1
2
 (𝑁𝑁 + 𝑁𝑃) + 1 
Here, N stands for the amount of atoms of the corresponding element.65 The 
nitrogen rule states that an odd nominal molecular mass also implies an odd 
number of nitrogen atoms.65   
In 2006, Kind and Fiehn showed the advantage of using isotopic abundance 
pattern as an additional filter for calculating elemental formulas.63 They com-
pared a MS with 3 ppm mass accuracy applying the isotopic pattern filter (2% 
error) to a MS with less than 1 ppm mass accuracy omitting the isotopic pattern 
as a filter. They demonstrated that high mass accuracy alone is insufficient in 
order to reduce the number of possible elemental formulas especially for candi-
dates with complex elemental compositions.63 Even a hypothetical mass spec-
trometer with 0.1 ppm mass accuracy was outperformed by the additional iso-
topic pattern filter.63 Therefore, the implementation of filters using the isotopic 
abundance pattern, removes most of the falsely assigned elemental formulas.63 
The isotopic pattern fit is evaluated by the calculation of the mSigma value in 
the SmartFormula tool from Bruker Daltonics. In the case of a perfect match the 
mSigma value is 0, whereas a value of 1000 means no match.  
After limiting the number of possible molecular formulas, whereby preferably 
only one elemental formula is left, available data bases like HMDB56, Metlin57 or 
ChEBI (Chemical Entities of Biological Interest)66 are searched for the chemical 
structure. However, the knowledge of the mass spectrometrist about the sam-
ples under investigation is an essential and mandatory requirement for the cor-
rect assignment of a chemical structure. As mentioned above, another aspect to 
positively identify an unknown signal is the corresponding fragmentation pat-
tern. Holcapek et al. summarized the fragmentation behaviors of individual func-
tional groups in 2010.67 Hence, MS/MS experiments can increase the 
knowledge on the identification of the signal under investigation.64 
Finally, the comparison to an authentic chemical standard is the last step in the 
identification workflow. The measured RT, isotopic pattern and fragmentation 
pattern from the standard should be compared to the unknown. The unambigu-
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ous identification of an unknown requires the additional measurement with an 
independent analytical method such as NMR. 
 4.4.2 Concrete examples for LC-MS based identification  
Here, the LC-MS based identification workflow and its significant role in metabo-
lomics is exemplarily shown. 
In the following, the identification procedures are partly adapted from Dettmer et 
al. 2013 and Zacharias et al. 2015, respectively.30,68 
In Dettmer et al. 2013, metabolic footprinting of the cell culture supernatants of 
20 human cancer cell lines and 4 primary cell cultures was conducted by means 
of high-resolution LC-QTOF-MS.68 Statistical analysis resulted in 391 differential 
features after correction for multiple testing. The 49 most significant features 
and five additional features were then identified according to Fig. 4.3. Here, ex-
emplarily the identification workflow of arginine, which was the most discriminat-
ing feature, is shown. Furthermore, MS/MS experiments were performed and 
the MS/MS spectra were compared to the METLIN library. The identification of 
the most significant features showed interesting insights into cancer metabo-
lism. It revealed extracellular arginine and nicotinamide as major discriminants 
between normal and neoplastic hepatocytes. Further, the observed significant 
differences in the assimilation of di- and tripeptides appeared to underscore the 
increased bioenergetic and biosynthetic demands of many cancers.68 These 
findings emphasize the importance of metabolite identification via high resolu-
tion LC-MS. 
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Figure 4.3: Exemplary workflow for the identification of unknown LC-ESI-qTOF-MS features that 
discriminate between different cell types. The Bruker tools SmartFormula and Compound 
Crawler were employed for the identification. The tentative identification of arginine was con-
firmed with an authentic chemical standard. 
In the study by Zaccharias et al. (2015), LC-QTOF-MS contributed to the identi-
fication of the most significant metabolite for the prognostication of acute kidney 
injury (AKI) patients after cardiac surgery with cardiopulmonary bypass.30 A well 
resolved NMR signal was found in plasma samples that distinguished patients, 
who developed AKI, from those that did not experience AKI. However, it was 
not possible to identify this signal by database searches or by 2D 1H 
TOCSY,1H−13C HSQC, and 1H−13C HMBC spectra, respectively. Therefore, 5 
AKI and 5 non-AKI plasma samples were investigated by LC-QTOF-MS. After 
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correction for multiple testing, 11 significant features remained. Identification 
was performed as shown exemplarily in Fig. 4.3 and standards were purchased 
for the most promising hits. MS/MS experiments were performed on both the 
standards and the plasma specimens for additional verification. Among the 
most discriminating features, the propofol metabolites propofol glucuronide and 
4-hydroxy-propofol-1-OH-D-glucuronide were positively identified. 1D 1H NMR 
reference spectra were acquired on these compounds and unambiguously veri-
fied the assignment of the NMR signal.30 
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5. Experimental section 
5.1 Materials 
Deionized water (PureLab Plus system, ELGA LabWater, Celle, Germany) cre-
atinine-D3 (C/D/N Isotopes, Pointe-Claire, Canada), HPLC-grade acetonitrile 
(ACN) were purchased from VWR International (Vienna, Austria). Formic acid, 
uric acid, 1-methyluric acid, phenylacetic acid, phenyllactic acid, 3-(4-
hydroxyphenyl)propionic acid, indoxyl-sulfate, creatine, creatinine, hippuric acid, 
guanidinoacetic acid, hypoxanthine, methylxanthine, kynurenic acid, DL-
kynurenine, DL-tryptophan, xanthurenic acid, 3-hydroxyanthranillic acid, 3-
indolacetic acid, 3,4-dihydroxy-L-phenylalanine, indole, DL-3-indolelactic acid, 
3-indolepropionic acid, indole-3-carboxaldehyde, 3-indolepyruvic acid, trypta-
mine, tryptophol, nicotinic acid, melatonin, 3-hydroxy-DL-kynurenine, 5-
hydroxyindole-3-acetic acid, 1,7-dimethylxanthine, serotonine hydrochloride, 
xanthine, nicotinamide, quinolinic acid, anthranilic acid, ammonium hydroxide 
and sodium hydroxide were purchased from Sigma-Aldrich/Fluka (Taufkirchen, 
Germany). Isopropanol (VWR), propofol (Toronto Research Chemicals, Toron-
to, Ontario, Canada). 
5.2 Sample preparation 
If not indicated otherwise, all urine specimens were diluted 1:4 with deionized 
water either directly in 1.5-mL glass vials with 0.2-mL micro-inserts (Machery-
Nagel, Düren, Germany) or in micro-reaction tubes and subsequently trans-
ferred into the glass vials.  
5.3 Instrumentation 
5.3.1 HPLC-ESI-TOFMS 
A Thermo Scientific Dionex Ultimate 3000 UHPLC system (Idstein, Germany) 
consisting of the HPG3400 RS pumping system, the TCC-3000 RS column ov-
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en and the WPS3000TFC autosampler was coupled to a Maxis Impact QTOF-
MS (Bruker Daltonics, Bremen, Germany) through an ESI source. A KinetexTM 
C18 column (100 mm x 2.1 mm id x 2.6 µm C18 1000, Phenomenex, Aschaf-
fenburg, Germany) with a SecurityGuard ULTRA C18 cartridge (Phenomenex) 
as a pre-column was applied to separation in chapter 6 and to the fingerprinting 
measurements in chapter 8. The column oven temperature was set at 35°C. 
The chromatographic separation was accomplished by applying 0.1% (v/v) for-
mic acid in water as mobile phase A and 0.1% (v/v) formic acid in ACN as mo-
bile phase B at a flow rate of 0.3 mL/min. Elution was accomplished by the fol-
lowing ACN gradient unless stated otherwise in the text: 0-40% in 10 min, 40-
100% in 2 min, 100% for 5 min, back to 0% in 0.1 min, 5 min equilibration. An 
injection volume of 5 µL was used unless otherwise noted in the text. The ESI 
source was operated in positive mode applying the following settings for the 
source and the mass spectrometer: drying gas: nitrogen with a temperature of 
220 °C and a flow rate of 10 L/min; pressure of the nebulizer gas (nitrogen): 2.6 
bar; end plate offset: 500 V; capillary voltage: 4500 V; mass range: 50-1000 
m/z; acquisition rate: 5 spectra/s. Before the measurements, an external cali-
bration of the mass spectrometer was implemented using sodium formate clus-
ters (10 mM). Therefore, 12.5 mL of water, 12.5 mL of isopropanol, 50 µL of 
formic acid (conc.) and 250 µL of 1M NaOH were mixed.  Additionally, each run 
was started with an injection of the sodium formate solution by means of a six-
port valve for internal recalibration (see section 4.4.1). 
5.3.2 HPLC-ESI-QqQMS 
A 1200 SL HPLC (Agilent, Böblingen,Germany) was coupled to an Applied Bio-
systems 4000 QTRAP mass spectrometer (Sciex, Darmstadt, Germany) via a 
TurboV ESI source operating either in positive or negative ionization mode. For 
separation a Waters (Eschborn, Germany) Atlantis T3 column (2.1 x 150 mm 
i.d., 3 µm) at 25°C was used, applying 0.1% (v/v) formic acid in water as mobile 
phase A and 0.1% (v/v) formic acid in ACN as mobile phase B at a flow rate of 
0.4 mL/min. The elution of the analytes detected in positive and negative mode 
was achieved by the following ACN gradient: 0% to 50% in 1 min, 50% for 5 
min, back to 0% in 0.1 min, 4 min equilibration. This gradient is equivalent to the 
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gradient used by Zhu et al. (2011).69 An injection volume of 10 µL was utilized. 
The MS parameters for each metabolite were optimized by direct infusion via a 
syringe pump (Harvard Apparatus, Holliston, MA, USA).  
5.3.3 Miscellaneous 
In the course of this doctoral research work the following other lab equipment 
was utilized: a heater with two heating blocks (Haep Labor Consult, Bovenden, 
Germany), a vortexer (lab dancer, IKA-Werke GmbH, Staufen, Germany) and a 
model himac CT15RE centrifuge from Hitachi (Düsseldorf, Germany).  
5.4 Data analysis 
5.4.1 Software 
DataAnalysis version 4.1 (Bruker Daltonics) was utilized for manual examination 
and processing of the HPLC-TOF-MS chromatograms and mass spectra, com-
pound extraction, internal recalibration of the mass spectra, and calculation of 
accurate masses, elemental formulas and mSigma values as well as for feature 
extraction from the chromatograms by the Find Molecular Feature (FMF) algo-
rithm. ProfileAnalysis version 2.2 (64-bit) (Bruker Daltonics) was employed for 
feature alignment. Bucket tables were then exported and further analyzed with 
the R package version 3.1.170 and Excel (Microsoft Corporation, Redmond, 
WA). Bland Altman plots as well as basic statistics e.g. the calculation of rela-
tive standard deviations (RSDs), paired student’s t test, spearman rank correla-
tion coefficients (SCC) as well as Pearson correlation coefficients was per-
formed with Excel. R was used to generate box plots and Venn diagrams as 
well as to perform principle component analysis (PCA), hierarchical cluster 
analysis by using Pvclust71, Shapiro-Wilk test and to calculate false discovery 
rates (FDRs) according to Benjamini and Hochberg51 using MULTTEST72.  
MassLynx (Waters, Eschborn, Germany) was used for manual reintegration and 
quantification of specific analytes in chapters 6 and 8. The Analyst (Applied Bio-
systems/MDS Sciex, Darmstadt, Germany) software was used for calculating 
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calibration curves, quantitative analysis and manual reintegration of analytes in 
chapter 7.  
5.4.2 Calibration curves 
For each standard the corresponding SIL-IS or an appropriate IS, which was 
structurally similar or was closely eluting, was used to normalize the peak area. 
Calibration curves were generated for each standard by plotting the ratio of the 
standard area and the IS area against the ratio of the absolute standard con-
centration and the IS concentration. This was followed by a linear regression 
analysis with a 1/x weighting to determine the coefficient of correlation R. LLOQ 
and ULOQ limited the linear range for each standard, whereby a S/N of 8/1 and 
a deviation smaller than 20% were utilized according to the FDA Guide for Bio-
analytical Method Validation.73     
5.4.3 Retention time corrector (RTcorrector) 
The RTcorrector is an in-house written tool implemented by Alexandra Holler. 
The tool corrects for retention time shifts between different measurement 
batches. It was implemented for untargeted LC-MS data. In order to correct the 
RT of a certain bucket table as shown in Fig. 4.3, a bucket table is loaded as 
reference table into the tool. Then a bucket table will be corrected to fit the 
bucket table loaded as reference. Next, metabolites that serve as reference to 
compare the RTs are selected (Main Metabolites function). These should be 
metabolites which are abundant in all samples and not in detector saturation. 
They can be found in the given bucket tables by using a m/z and RT window. 
The Main Metabolite shift is calculated in order to predict the respective shift of 
all buckets. Further it can be selected if the shift should be handled as an abso-
lute value (e.g. all peaks are shifted 2 min towards higher RTs) or as ratios (e.g. 
the retention times of the peaks are doubled). If there are more than one Main 
Metabolite, one can select if either a linear model to predict the shift depending 
on retention time or a constant shift using the median or mean of the Main Me-
tabolite shifts are applied to correct the bucket tables. This tool was successfully 
used for the untargeted LC-MS bucket table generated in chapter 8.3.2. The 
Python interface is shown in Figure 5.1. 
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Figure 5.1: RT corrector Python interface. On the left side the reference file, the bucket table 
which should be corrected and the main metabolites are entered. On the right side, settings for 
the calculation are selected.  
 
5.4.4 Bucket assigner    
For comparison of samples from more than one batch, an in-house written 
bucket assigner (written by Sebastian Mehrl and Leonhard Heiziger) was used 
to align the bucket tables of the respective sample sets (see Fig. 5.2). This was 
applied to all experiments were the samples were measured in more than one 
batch. Features were individually aligned based on closeness within a manually 
specified m/z (e.g. 5 mDa) and retention time window (e.g. 0.1 min). Features in 
both bucket tables were marked if they were not assigned or multiple times as-
signed.74 
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Figure 5.2: BucketAssigner Python interface with resulting bucket table is shown. 
5.5 Validation methods 
5.5.1 Hierarchical cluster analysis 
 
Unsupervised clustering is a widely used statistical tool in metabolomics. An 
unsupervised method is independent of class label information or example 
based grouping properties of the data. Therefore, it is an ideal method to identi-
fy novel patterns in data.75 For clustering, a statistical distance function is re-
quired in order to partition a dataset into several subclasses or clusters.76 Hier-
archical and non-hierarchical are the two main clustering algorithms, whereby 
both divide the dataset into subgroups so that data with the same metabolic 
profile are clustered together.76 In hierarchical clustering the grouped dataset is 
represented by a binary tree-like dendrogram.75 The similarity of two observa-
tions is determined by a specific metric ,e.g. Euclidian, defined as geometric 
distance between two components, or Manhattan, the sum of the absolute dis-
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tances of two vector values.75 Iteratively the most similar observations are either 
grouped in one cluster or as neighbors. Ward’s method clustering is a very effi-
cient algorithm for hierarchical clustering. It tries to minimize the sum of squares 
of any two clusters that can be formed at each step.75 
5.5.2 Bland-Altman plot 
A Bland-Altman plot is a graphical approach to study the extent of agreement or 
disagreement between two different analytical techniques.77,78 This method can 
also be applied to check the repeatability of one analytical technique or to com-
pare the measurement by two operators.77 Bland and Altman introduced this 
method in 1983 due to the lack of an appropriate analysis method to investigate 
the agreement of two measurements that cannot be fully captured by correlation 
coefficient and linear regression.79  
In a Bland-Altman plot the y-axis represents the difference between the output 
variable x of the two paired measurements (x1-x2) and the corresponding aver-
age is plotted on the x-axis (x1+x2)/2).
2 For an easy visualization the mean dif-
ference (?̅?), and the limits of agreement, which are defined as the mean differ-
ence ±1.96 times the standard deviation (?̅?±1.96*σ), are depicted as horizontal 
lines in the plot.77 These limits were determined under the assumption that the 
differences are normally distributed and therefore 95% of the differences are 
expected to lie within these limits.77 As stated by Kaspar et al., six different 
types of Bland-Altman plots can be categorized.80 In order to distinguish the 
plots graphically, the absolute mean differences, the scattering of the differ-
ences (randomly or proportionally) and the relative mean differences (ratio of 
the mean difference and the averaged mean of all couples, on a percentage 
basis) are used. According to Kaspar et al., a type A plot represents the mean 
difference of almost zero, a random scattering of all differences and a relative 
difference of ≤15%.80  
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6. Evaluation of dilution and normalization 
strategies to correct for urinary output in HPLC-
HRTOFMS metabolomics 
6.1 Introduction 
Urine is a common matrix employed in large-scale human metabolomics stud-
ies, because it can be obtained non-invasively.3,81 As products of cellular pro-
cesses and responses, urinary metabolites are tightly related to phenotypes.82 
However, urinary output can differ greatly due to various processes involved in 
regulating the body’s water and solute content. Factors affecting urinary metab-
olite abundance include among others water intake by drinking and eating, wa-
ter loss due to respiration, perspiration and defecation, age, solute intake and 
the urine-concentrating ability of the kidneys.3 As a result, urinary metabolite 
concentrations can vary widely. Therefore, untargeted analysis of urine is chal-
lenging, because inter-individual differences in metabolite abundance are not 
necessarily related to the phenotype under investigation and may actually mask 
“true” metabolic differences. Consequently, normalization strategies are neces-
sary to reveal true biological variances.4 Commonly, creatinine is utilized for this 
task, as it is produced at a constant rate and excreted - at least in healthy indi-
viduals - by glomerular filtration only without being reabsorbed or secreted in 
the renal tubule.5  However, urinary creatinine concentration is influenced by 
various factors, including  age, sex, muscle mass, diet, kidney function and wa-
ter excretion.5 Alternatively, the osmolality, i.e. the molar sum of all solutes in 
urine, can be applied to correct for urinary output.4,6  
The procedure most commonly employed in LC-MS based metabolomics of 
urine uses a uniform pre-acquisition dilution of the urine specimens followed by 
post-acquisition normalization to either creatinine concentration or to the sum of 
all integrals of each sample. However, the selection of a proper pre-acquisition 
dilution factor is often difficult. On the one hand, analysis of highly concentrated 
specimens may result in column overloading, peak overlapping or ion suppres-
sion, which cannot be corrected by post-acquisition normalization. On the other 
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hand, uniform dilution may result in overly dilution of less concentrated urine 
specimens and, hence, failure to detect low-abundant analytes.  
Lutz et al. suggested pre-analytical adjustment of urine specimens to an equal 
creatinine concentration by individual dilution, observing improved repeatability 
of retention times and area integrals in the profiling of dextromethorphan glucu-
ronides.83 Chen et al. proposed the adjustment of injection volumes to obtain 
uniform creatinine and, therefore, roughly equal overall metabolite amounts on 
the column for every sample. The acquired data were then normalized to the 
“MS total useful signal” (MSTUS).84 However, urinary creatinine concentration 
can easily differ by a factor of 20 up to 100. Hence, injection volume range and 
column capacity can be limiting factors. Mattarucchi et al. diluted urine speci-
mens according to the MSTUS measured in a preceding run.85 More recently, 
Edmands et al. proposed pre-acquisition normalization to specific gravity, i.e. 
the weight of solids in urine, and evaluated different post-acquisition normaliza-
tion methods to improve the identification of biomarkers, with post-acquisition 
normalization to specific gravity yielding the highest number of discriminant fea-
tures.86 Furthermore, Chetwynd et al. recently recommended pre-analytical ad-
justment to uniform osmolality.87  
To date, the various strategies proposed to correct for variation in urinary output 
prior to MS-based metabolic fingerprinting have not been compared systemical-
ly with regard to their capacity of keeping the number of missing values in the 
data to a minimum and detecting a maximum of significantly discriminating fea-
tures that allow accurate classification of samples. Here, we compared pre-
acquisition dilution of spot urinary specimens to either a uniform creatinine con-
centration or osmolality without any further normalization of the acquired data to 
the common practice of uniform dilution followed by post-acquisition normaliza-
tion to creatinine, osmolality, or sum of all integrals. Urine osmolality was cho-
sen over specific gravity, as the former is less affected by the presence of large 
and heavy molecules such as glucose and proteins, thus reflecting more the 
number than the weight of solutes in urine. To test the effect of the various 
strategies on sample classification, we investigated spot urine specimens from 
both an apparently healthy cohort as well as two different cohorts suffering from 
chronic kidney disease (CKD). 
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Preparation of samples from batch 4 was carried out by Nadine Nürnberger 
from batch 5 by Lisa Ellmann. For the Random Forest classification as well as 
the heat map, the R script from Helena U. Zaccharias was applied.  
This chapter was published in the Journal Analytical and Bioanalytical Chems-
itry in 2016.74 Text passages were taken verbatim from this publication.  
6.2 Materials and Methods 
6.2.1 Chemicals.  
Deionized water (PureLab Plus system, ELGA LabWater, Celle, Germany) was 
used to prepare mobile phase A, a 1.5 mM stock solution of creatinine-D3 
(C/D/N Isotopes, Pointe-Claire, Canada), and dilutions of the urine specimens. 
HPLC-grade acetonitrile (ACN) was purchased from VWR International (Vienna, 
Austria), formic acid from Sigma-Aldrich/Fluka (Taufkirchen, Germany). 
6.2.2 Urine specimens 
Human urine specimens were collected with informed consent from two differ-
ent patient cohorts. The initial patient group comprised baseline urine speci-
mens from 25 randomly selected patients from the clinical Trial to Reduce Car-
diovascular Events with Aranesp Therapy (TREAT).15 The TREAT had enrolled 
at 623 sites in 24 countries from the Americas, Australia and Europe a total of 
4038 patients with type 2 diabetes, CKD with an estimated glomerular filtration 
rate (eGFR) of 20-60 mL/min/1.73 m2 of body-surface area, and anemia (hemo-
globin level, ≤11.0 g/dL). As a control group, we used 25 randomly chosen urine 
specimens from a group of 228 apparently healthy volunteers that had been 
selected at random through the Regensburg population registry within the 
framework of the German National Cohort (NC) (www.nationale-kohorte.de). To 
validate the obtained classification model and features identified to distinguish 
healthy from affected individuals, a second set of 25 urine specimens each from 
the TREAT and the NC cohort was analyzed. Finally, 50 urine specimens from 
patients enrolled into the German Chronic Kidney Disease (GCKD) study were 
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examined.14 The group included patients with an eGFR below 60 mL/min/1.73 
m2, with and without type 2 diabetes as well as with and without increased al-
buminuria (> 300 mg/mL and < 30mg/ml, resp.).  
6.2.3 Sample preparation 
Urine samples were prepared in 1.5-mL vials with a 200-µL conical glass insert 
(Machery-Nagel, Düren, Germany). A first set of 25 urine specimens each from 
the TREAT and the NC cohort were diluted uniformly 1:4 with deionized water 
(batch 1) or adjusted before measurement to either a uniform osmolality (batch 
2) or a uniform creatinine concentration (batch 3). For uniform 1:4 dilution in 
batch 1, 10 µL of an aqueous creatinine-D3 solution (1.5 mM) was added to 10 
µL of urine followed by 20 µL of water resulting in a creatinine-D3 concentration 
of 375 µM. For batches 2 and 3, volumes of urine and water added to 17 µL of 
an aqueous creatinine-D3 solution (1.5 mM) were varied for each specimen to 
reach a final volume of 50 µL and either a uniform osmolality of 100 mOsmol 
(batch 2) or a uniform endogenous creatinine concentration of 1.5 mM (batch 
3). The target values of 1.5 mM creatinine or 100 mOsmol were chosen, be-
cause these were, with a few exceptions (see below), the lowest measured val-
ues in the sample set. The resulting concentration of creatinine-D3 was 510 µM. 
Due to limited sample availability seven urine specimens (N=3 for batch 2, N=4 
for batch 3) were individually diluted to a final volume of 25 µL each while main-
taining the target creatinine or osmolality values. In these cases the creatinine-
D3 standard (8.5 µL) was added beforehand to the insert and the solvent was 
evaporated.  
In batch 3, two specimens (NC 6, NC 25) were not diluted due to low creatinine 
concentrations of 0.9 mM and 1.5 mM, respectively. For the dilution to a uniform 
osmolality, one specimen (NC 25) already possessed an osmolality of 100 
mOsmol and, therefore, was measured unmodified. These three samples were 
prepared with a final volume of 25 µL with pre-evaporated internal standard (IS) 
(8.5 µL) as described above.  
To assess dilution repeatability, 3 NC samples with low, medium and high creat-
inine concentrations (0.9 mM, 12.0 mM, 33.4 mM) were diluted 5 times each 
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and analyzed. Additionally, an independent urine quality control sample (QC) as 
well as a blank (H2O) were injected repeatedly over the analysis of each batch 
(n=6 and n=5, respectively). The QC sample was prepared once (1:4 dilution).  
In order to validate markers whose concentrations differed significantly between 
patients and controls, a second set of 25 urine specimens each from the 
TREAT and the NC cohort, respectively, was analyzed (batch 4). Samples were 
adjusted to a uniform target creatinine concentration of 2 mM because this was 
the lowest measured value in this sample set. Due to sample limitation, 4 spec-
imens were diluted to a final volume of 25 µL and 3 specimens were not diluted 
at all due to low creatinine levels, but prepared in 25 µL as described above. In 
addition, 50 urine specimens from the GCKD study and the 25 urine specimens 
from the NC cohort that had already been part of batch 4, were examined 
(batch 5). The urine specimens were diluted to the lowest creatinine concentra-
tion, which for this batch was 1mM. Due to low creatinine levels, 2 GCKD spec-
imens were not diluted at all. 2 NC samples were pre diluted 1/10 due to high 
creatinine concentrations prior to final dilution to 1 mM. An overview of all em-
ployed samples is given in Table 6.1. 
Table 6.1. Overview of all the employed sample sets, their respective batch numbering and 
dilution methods. Reprinted from Vogl et al. 2016.
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6.2.4 Creatinine quantification 
For the TREAT and NC urine specimens, creatinine was determined by LC-MS 
based isotope dilution analysis (IDA) upon addition of creatinine-D3 to each 
sample. The endogenous creatinine concentration was calculated by the ratio of 
the peak area of endogenous creatinine to the peak area of creatinine-D3 and 
multiplied by the concentration of creatinine-D3. Integration of creatinine and 
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creatinine-D3 peaks was performed using QuantLynx V4.1 (Waters Inc., Milford, 
MA). For batch 5, the creatinine concentrations determined by Synlab (SYNLAB 
Holding Deutschland GmbH, Augsburg, Germany) were used for dilution to a 
uniform creatinine concentration. 
6.2.5 Osmolality 
Measurements of urine osmolality were performed at the Department of Clinical 
Chemistry and Laboratory Medicine of the University Clinic Regensburg by de-
termination of the freezing point depression using the Advanced Osmometer 
model 2020 (Advanced Instruments, INC, Norwood, MA). 
6.2.6 LC-MS Analysis 
A Thermo Scientific Dionex Ultimate 3000 UHPLC system (Idstein, Germany) 
was coupled to a Maxis Impact QTOF-MS (Bruker Daltonics, Bremen, Germa-
ny) through an ESI source. Analytes were separated on a KinetexTM C18 col-
umn (100 mm x 2.1 mm id x 2.6 µm C18 1000, Phenomenex, Aschaffenburg, 
Germany) at 35 °C applying 0.1% (v/v) formic acid in water as mobile phase A 
and 0.1% (v/v) formic acid in ACN as mobile phase B at a flow rate of 0.3 
mL/min. Elution was accomplished by the following ACN gradient: 0-40% in 10 
min, 40-100% in 2 min, 100% for 5 min, back to 0% in 0.1 min, 5 min equilibra-
tion.  A shorter ACN gradient was implemented for creatinine quantification:  0-
100% in 2 min, 100% for 5 min, back to 0% in 0.1 min, 5 min equilibration. An 
injection volume of 5 µL was used for metabolite fingerprints, whereas for creat-
inine quantification only 0.1 µL were injected.   
Electrospray ionization was performed in positive mode using the following set-
tings to operate the source and the mass spectrometer: drying gas: nitrogen 
with a temperature of 220 °C and a flow rate of 10 L/min; pressure of the nebu-
lizer gas (nitrogen): 2.6 bar; end plate offset: 500 V; capillary voltage: 4500 V; 
mass range: 50-1000 m/z; acquisition rate: 5 spectra/s. Before the measure-
ments, an external calibration of the mass spectrometer was implemented using 
sodium formate clusters (10 mM sodium formate in 50:50 v/v water/ isopropa-
nol). Additionally, each run was started with an injection of the sodium formate 
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solution by means of a six-port valve for internal recalibration. Mass spectral 
resolution of R=27000 was obtained. Samples were measured in random order.  
6.2.7 Data Analysis 
Mass spectra were internally recalibrated based on the sodium formate clusters 
analyzed at the beginning of each run using Bruker Data Analysis V4.1 (Bruker 
Daltonics, Bremen, Germany). Features were then extracted from the chroma-
tograms with the “find molecular feature” algorithm using the following parame-
ters: signal-to-noise threshold: 2; minimum compound length: 20 (minimum 
number of spectra per compound); correlation coefficient: 0.7 (minimal time cor-
relation needed for peak clusters to be combined to one charge state); smooth-
ing width: 0 (number of spectra used by the chromatographic peak finder for 
smoothing). Profile Analysis V2.1 (64-bit) (Bruker Daltonics) was employed for 
feature alignment. All features, called buckets by the software, between 0.01-12 
min and 50-1000 m/z were aligned. Each sample batch was aligned separately 
employing the advanced bucketing option with a time and mass window of 0.2 
min and 5 mDa, respectively, except for batch 1, for which a mass window of 20 
mDa was used. Buckets were only incorporated in the final bucket table if they 
were detected in at least 10% of the samples (bucket filter “value count of buck-
et” in Profile Analysis). Accuracy of bucketing was verified by recovery of 4 
common urine metabolites (creatinine, uric acid, hippuric acid, tryptophan). 
Bucketing was considered to be accurate if all 4 metabolites were found in eve-
ry sample. Bucket tables were exported from Profile Analysis as txt-files and 
further reduced by removing background signals and features found only in a 
limited number of samples. Peaks detected in the blank samples (N=5) with an 
intensity exceeding 20% of respective signals in the urine samples were ex-
cluded from the data. For this, the median of the respective peak in the blanks 
was compared to the median of the peak in the urine samples. Additionally, only 
features found in at least 80% of the samples (40 out of 50 samples for batch 1-
4, respectively 60 out of 75 for batch 5), were used for statistical analysis. All 
missing values (zero values) were substituted with NA for “not available”. Statis-
tical data analysis was performed using the R package version 3.1.170 and Ex-
cel (Microsoft Corporation, Redmond, WA). A two-sided Welch t-statistic was 
6. Evaluation of dilution and normalization strategies to correct for urinary output 
in HPLC-HRTOFMS metabolomics 
53 
 
calculated to obtain raw p-values with the R package MULTTEST72. These p-
values were adjusted for multiple testing by controlling the false discovery rate 
at the 5% level according to Benjamini and Hochberg.88 The significant features 
were displayed in a heat-map generated with an in house written method. Venn 
diagrams were created using the R package GPLOTS.89 Hierarchical clustering 
of data was performed with the R package PVCLUST71 employing Manhattan 
distances and the Ward clustering method. Before clustering, missing values 
were imputed by the minimum intensity found in the respective batch divided by 
ten and the data were scaled (mean centered). To limit the computation time, 
the number of bootstrap samples was set to 1000. 
For comparison of samples from more than one batch, an in house written 
bucket assigner was used to align the bucket tables of the respective sample 
sets. This was applied to the two sample sets diluted to a uniform creatinine 
concentration (batch 3 and 4). Similarly, batch 5, consisting of samples from an 
independent patient cohort, was aligned to the previously generated bucket ta-
ble of batches 3 and 4. Features were individually aligned based on closeness 
within a manually specified m/z (5 mDa) and retention time window (0.1 min). 
Features in both bucket tables were marked if they were not assigned or multi-
ple times assigned. For the combined batches 3 and 4, 210 features  were not 
assigned and excluded from further analysis, while the corresponding number 
of features excluded for the combined batches 3, 4 and 5 was 522, resulting in 
bucket tables consisting of 524 and 437 features, respectively. None of the fea-
tures was assigned multiple times. For further analysis, the mean retention 
times of the assigned features and their mean m/z value were used. The 
aligned batches 3, 4, and 5 were combined, tested for the presence of normal 
distribution applying the Shapiro-Wilk normality test in R, and then Quantile 
normalized using the R package AFFY90. Classification employing a Random 
Forests (RF) classifier91 provided in the R-package RANDOMFOREST92 was 
only applied to assigned features. The internal parameters of the RF classifier 
were set to default. (number of trees used: 500, number of variables tried at 
each split: 20) Missing values were imputed as described above. 
For batches 3 and 4, permutation tests, as outlined in Zacharias et al. 93, ena-
bled an estimation of the significance of the obtained classification results by 
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comparing the classification accuracies obtained for the original non-permuted 
and the permutated data. The class labels of the training set were randomly 
permutated for each run and the trained RF classifier was used for subsequent 
classification of the test set. The permutation tests were performed 10 times in 
total. The mean values and standard deviations of the average overall classifi-
cation accuracy and the corresponding error rates for both groups were calcu-
lated for the training and test set, respectively.  
For the analysis of retention time shifts, retention times of creatinine, uric acid, 
tryptophan, uric acid, and hippuric acid were determined using the Quant Anal-
ysis software from Bruker.  
6.3 Results and Discussion 
6.3.1 Creatinine Quantification 
Creatinine was quantified by isotope dilution analysis. Creatinine concentrations 
for batch 1 (constant 1:4 dilution) ranged from 0.9 to 33 mM. The analysis of the 
QC sample in this batch yielded a relative standard deviation (RSD) of 3.7% 
(N=6). The respective RSD values for the QC samples in batches 2 (dilution to 
constant osmolality) and 3 (dilution to constant creatinine) were 4.6% and 3.9%. 
The inter-batch precision of the QC sample analysis for all three batches was 
4.3% (N=18). Moreover, the analysis of the dilution replicates within batches 1 – 
3 yielded RSD values below 7.5%.  
6.3.2 Basic characteristics of the first sample set 
The osmolality in the first sample set (see Table 6.1, normalization set) of 25 
NC and TREAT specimens each ranged from 107 to 1119 mOsmol. A signifi-
cant correlation (r = 0.657, p = 2.24*10-7) between creatinine and osmolality 
across all samples was observed (Figure 6.1 A). Examining the NC and the 
TREAT separately increased the correlation between creatinine and osmolality 
in the former (r=0.793, p = 2.24*10-6), while a weaker, albeit still significant cor-
relation was observed for the latter (r=0.5, p = 0.011) (Figure 6.1 B). 
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Figure 6.1: Linear correlation between osmolality and creatinine concentrations of the measured 
samples. (A) For TREAT and NC specimens combined. (B) Separately for TREAT and NC 
specimens. Reprinted from Vogl et al. 2016.
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Furthermore, osmolality was significantly lower (t-test, p= 4.89*10-5) in the 
TREAT (389 mOsmol ± 83 mOsmol) than in the NC specimens (660 mOsmol ± 
293 mOsmol) (Figure 6.2 A). Urinary osmolality values below 400 mOsmol, as 
observed for the TREAT patients, are a diagnostic marker for tubular damage.94  
 
Figure 6.2: Boxplots representing the distribution of osmolality values (A) and creatinine concen-
trations (B) for TREAT and NC urine specimens. Reprinted from Vogl et al. 2016.
74
 
Urinary creatinine concentrations between the two groups were comparable 
(p>0.05) (Figure 6.2 B).  The urinary creatinine concentrations of the TREAT 
patients were not decreased compared to the NC cohort. This is likely due to 
the fact that in patients with CKD creatinine is not only excreted by glomerular 
filtration but also by renal tubular secretion.95,96 Furthermore, patients with re-
duced glomerular filtration often also show a reduction in urinary output. After 
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uniform 1:4 dilution of the specimens, creatinine concentrations ranged from 
0.2-8.3 mM, whereas dilution to a uniform osmolality of 100 mOsmol yielded a 
more narrow range of 0.6-5.4 mM creatinine (Figure 6.3).  
 
Figure 6.3: Boxplot illustrating the distribution of urinary creatinine concentrations for the TREAT 
and NC specimens after uniform 1:4 dilution (method A) or dilution to a uniform osmolality value 
(method E). Reprinted from Vogl et al. 2016.
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Lutz et al. observed in contrast to the use of crude urine smaller retention time 
shifts over time for urine specimens diluted to a uniform creatinine concentra-
tion.83 However, one must keep in mind that the authors employed a sample 
enrichment step by means of an online trap column. In our study, retention did 
not depend on the dilution strategy but was stable for all tested dilution methods 
as illustrated in Figure 6.4, which shows the retention times of 4 common urine 
metabolites (creatinine (Panel A), uric acid (Panel B), hippuric acid (Panel C), 
and tryptophan (Panel D)) vs. the respective original creatinine concentrations 
of the urine specimens of batches 1, 2 and 3. Repeatability (RSD) of retention 
times across all 3 batches for the 4 metabolites ranged between 0.6% and 
8.3%. The retention time shift of approximately 0.2 min observed for creatinine 
and uric acid resulted from elution of these metabolites close to the hold-up 
time.   
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Figure 6.4: Retention time of 4 common urine metabolites creatinine (Panel A), uric acid (Panel 
B), hippuric acid (Panel C), tryptophan (Panel D) vs. the respective original creatinine concen-
tration of the urine sample from batch 1, 2 and 3. Reprinted from Vogl et al. 2016.
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6.3.3 Effects of different dilution strategies on missing values 
After feature extraction and alignment of the sample batches prepared by uni-
form dilution (batch 1), dilution to uniform osmolality (batch 2) or uniform creati-
nine concentration (batch 3), the resulting raw bucket tables were corrected for 
background signals and then examined for the number of missing values (MVs), 
which may originate from errors by the peak picking and alignment algorithm or 
may indicate that the feature was not detected in the sample above the limit of 
detection.  
The evaluation of MV counts was performed with the background corrected 
bucket tables that incorporated all features (buckets) that were detected in at 
least 10% of the samples. This resulted in a high number of missing values with 
an average of 4833 MVs per sample in batch 1, 4818 MVs for batch 2, and 
3374 MVs for batch 3. However, the number of extracted features was also the 
lowest for batch 3 due to the overall higher dilution of the samples. The inter-
sample variability of the MV count was also decreased with a relative standard 
deviation (RSD) of 6 % in batch 3 compared to 7.6 % for batch 2 and 16.7 % for 
batch 1. The MV count per sample correlated significantly with the creatinine 
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concentration and the osmolality in the undiluted specimens. For the uniformly 
diluted samples (batch 1), the number of MVs decreased with higher creatinine 
concentrations (r = - 0.843, p = 1.69*10-14) or higher osmolality values (r = - 
0.775, p = 3.78*10-11), respectively (see Figure 6.5 panel A and B). This indi-
cates that samples with a low osmolality or creatinine concentration were overly 
diluted, resulting in failure to detect lower abundant features. In contrast, these 
correlations were less distinctive for the samples diluted to a constant osmolality 
(see Figure 6.5 panel C and D). Noticeably, the correlation of the MV count with 
the creatinine concentration in undiluted samples (r= -0.634, p = 7.38*10-7) and 
the creatinine concentration in samples diluted to uniform osmolality (r= -0.755, 
p = 2.38*10-10; Figure 6.5C) were still significant, while a correlation with the 
osmolality in the original specimens was no longer observed (r = -0.179, p = 
0.212; Figure 6.5D). The still observed correlation with the creatinine concentra-
tion indicates that this dilution strategy does not completely normalize for uri-
nary output, but some features seem to be lost due to the dilution. Only the 
samples diluted to a uniform creatinine concentration (batch 3) revealed neither 
a correlation of the MV count with the original creatinine concentration (r = 
0.216, p = 0.133) nor with osmolality (r = - 0.074, p = 0.608) (see Figure 6.5 
panel D and E).  
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Figure 6.5: Impact of dilution strategies (A, B: uniform 1:4 dilution; C, D: dilution to a uniform 
osmolality value of 100 mOsmol; E, F: dilution to a uniform creatinine concentration of 1.5 mM) 
on correlation of missing values with creatinine concentration (A,C,E) and osmolality (B,D,F), 
respectively. Reprinted from Vogl et al. 2016.
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6.3.4 Evaluation of different dilution strategies and normalization 
methods 
To reduce the MV count in the data matrices for further data evaluation, a strin-
gent feature filter was applied including only features in the bucket table that 
were found in at least 40 out of 50 samples. The uniformly diluted samples 
(batch 1) were then normalized after LC-HRTOFMS analysis testing different 
post-acquisition normalization methods. In detail, no normalization (A) was 
compared to normalization to creatinine concentration (B), osmolality (C) and 
sum of all integrals (D). These post-acquisition methods were compared to the 
two pre-acquisition methods (batch 2 – E and batch 3 – F). Table 6.2 lists all 
tested methods (A-F) with their corresponding number of features, number of 
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readings (number of features  number of samples), number of MV relating to 
the number of readings, and number of features without MV. Furthermore, t-
tests with correction for multiple testing (FDR < 0.05) according to Benjamini 
and Hochberg88 were performed to test for features that were significantly dif-
ferent between NC and TREAT samples for each method. For methods A-D 
(batch 1), 726 features were extracted from all 50 samples, whereas for meth-
ods E (batch 2) and F (batch 3) 762 and 617 features, respectively, were ex-
tracted. The lower number of extracted features for method F (batch 3) is the 
result of the greater dilution of these samples.  
Table 6.2. Figures of merit for the different batches and normalization methods tested for the 
normalization set (batch 1-3) measured with LC-HRTOFMS. No normalization (batch 1, method 
A) was compared to normalization to creatinine concentration (batch 1, method B), osmolality 
(batch 1, method C) and the sum of all integrals (batch 1, method D). These post-acquisition 
methods were compared to the two pre-acquisition methods (batch 2 – E and batch 3 – F). For 
all the tested methods (A-F) the corresponding number of features, number of readings (number 
of features  number of samples), number of MV relating to the number of readings, and num-
ber of features without MV are shown. Furthermore, t-tests with correction for multiple testing 
(FDR < 0.05) according to Benjamini and Hochberg
88
 were performed to test for features that 
were significantly different between NC and TREAT samples for each method. Reprinted from 
Vogl et al. 2016.
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The numbers of significant features for the post-acquisition methods (batch 1, 
method A-D) indicate that no normalization (A) and normalization to creatinine 
(B) yielded a highly similar number of significant features, namely 194 and 192, 
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respectively, whereas normalization to osmolality (batch 1, method C) yielded 
237 significant features. The best performance was observed with normalization 
to the sum of all integrals with 249 significant features. The latter approach does 
not only correct for different urinary output, but it also accounts for injection var-
iability. Our results are in accordance with the results of Warrack et al., who ob-
served no improvement in the principal component analysis (PCA) group differ-
entiation with normalization to creatinine in comparison to no normalization, 
whereas the normalization to osmolality resulted in an improvement.4 Chen et 
al. described that the normalization to the sum of all integrals yielded the best 
intergroup clustering and the lowest intragroup bias in the PCA score plot 
amongst the tested post-acquisition methods with identical injection volume. 
Interestingly, normalization to creatinine concentration was the least effective 
method.84 
Although the total number of extracted features was the smallest for method F 
(batch 3), the number of significantly different features (FDR < 0.05) that distin-
guished NC from TREAT samples was, in terms of percentage, only slightly 
lower (33.7%) than for method D (batch 1). Interestingly, for method E (batch 2), 
only 211 (27.7%) of the detected features were significantly different between 
TREAT and NC, resembling the results obtained without normalization (batch 1, 
method A) (194/26.2%). This might have been caused by an insufficient correc-
tion for urinary output, as indicated by the remaining correlation with the MVs 
(see Figure 6.5 panel C), thus resulting in insufficient consideration of varying 
degrees of ion suppression or detector saturation in MS analysis and of failure 
to detect features due to overly dilution.  
We further tested how many significantly different features were shared by ap-
plication of the different normalization approaches. Comparing the results of the 
post-acquisition methods (B-D) yielded 137 significant features that were 
shared by all three post-acquisition methods (Figure 6.6A). Comparing the pre-
acquisition normalization methods with post-acquisition method D, 91 significant 
features were shared by all three methods (Figure 6.6B). Consequently, the 
Venn diagrams imply that the compared methods obtain similar sets of signifi-
cant features. However, some of the detected significant features are character-
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istic for the respective methods. Nonetheless, the overlap of significant features 
represents features that distinguish robustly the investigated phenotypes.  
 
Figure 6.6. Venn diagrams of the numbers of significant features that discriminate between CKD 
patients and healthy controls for the different normalization methods employed. (A) Overlap of 
post-acquisition methods applied to LC-HRTOFMS fingerprints recorded for uniformly 1:4 dilut-
ed urine specimens: method B, normalization to creatinine concentration; method C, normaliza-
tion to osmolality; method D, normalization to sum of all integrals. (B) Overlap of pre-acquisition 
methods E (dilution to a uniform osmolality value of 100 mOsmol) and F (dilution to a uniform 
creatinine concentration of 1.5 mM) with the post-acquisition method to the sum of all integrals 
(method D). Reprinted from Vogl et al. 2016.
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Additionally, the sum of all integrals was examined for batches 1, 2 and 3 using 
box plots (Figure 6.7). The sum of all integrals can be considered as a measure 
for the overall sample concentration as a composite of all metabolite concentra-
tions. The spread of the sum of all integrals over all samples is the largest with 
uniform dilution, decreases with dilution to a uniformly osmolality value, and is 
the smallest for dilution to a uniform creatinine concentration. Furthermore, the 
median for batch 3 is lower than for the other batches, because the samples of 
batch 3 had been diluted more. Overall, this plot illustrates that the dilution to a 
uniform creatinine value (batch 3) balanced the highly varying sample concen-
trations more than the dilution to a uniform osmolality value or a uniform 1:4 
dilution. This result is in agreement with the lower inter-sample variability of the 
MV count and the absent correlation of the MV count with creatinine concentra-
tion or osmolality in batch 3 as described above.   
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Figure 6.7: Boxplots representing the distribution of the sum of all integrals of the urine speci-
mens analyzed as a function of the pre-acquisition method used. Batch 1: uniform 1:4 dilution, 
no normalization; batch 2: dilution to a uniform osmolality of 100 mOsmol; batch 3: dilution to a 
uniform creatinine concentration of 1.5 mM. Reprinted from Vogl et al. 2016.
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To test the degree to which the different normalization methods impact group 
separation, hierarchical cluster analysis was employed. To assess the uncer-
tainty in hierarchical cluster analysis either multiscale bootstrapping resampling 
or ordinary bootstrapping resampling was used, allowing the calculation of ap-
proximately unbiased (AU) p-values and bootstrap probability (BP) values, re-
spectively.71 Both measures adopt values between 0 and 1 indicating how 
strong a given cluster is supported by the data. Clusters with an AU p-value 
>0.95 are existing at a significance level of alpha.97 To keep computation time 
reasonably short, the bootstrap sample size was set to 1000. For hierarchical 
cluster analysis, the data matrices obtained with method D (batch 1), E (batch 
2) and F (batch 3) were used (Figure 6.8). Here, only Method D was used as 
the only post-acquisition normalization method because it performed best 
amongst the post-acquisition methods. Two distinct clusters were anticipated for 
the NC and the TREAT. However, only dilution to a uniform creatinine concen-
tration (method F) yielded two distinct clusters representing only NC and 
TREAT samples, respectively.  
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Figure 6.8. Hierarchical cluster analysis of fingerprinting data employing the Manhattan distance 
as a distance measure. Method D: uniform 1:4 dilution followed by a normalization to the sum of 
all integrals; method E: dilution to a uniform osmolality of 100 mOsmol without any additional 
normalization; method F: dilution to a uniform creatinine concentration of 1.5 mM without any 
additional normalization. The TREAT and NC samples are marked with a blue and red box, 
respectively. Reprinted from Vogl et al. 2016.
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Contrary to dilution to a fixed creatinine concentration (method F), pre-
acquisition dilution to uniform osmolality (method E) and post-acquisition nor-
malization to sum of all integrals (method D) failed to separate CKD patients 
clearly from healthy controls. This seems to indicate that only method F can 
account effectively for the analytical consequences resulting from highly varying 
metabolite concentrations, such as ion suppression, detector saturation and 
column overloading. Nevertheless, method D should be considered as an alter-
native to method F because this method allows correction for injection volume 
variability. We also tested a combination of methods D and F but failed to detect 
any significant improvement over dilution to a fixed creatinine concentration only 
(data not shown). 
Recently, Chen et al. tested normalization methods with differential injection 
volumes calibrated by creatinine followed by either MSTUS normalization or 
normalization to sum of all integrals. Both methods were the most effective 
methods regarding inter- and intragroup clustering in PCA amongst all investi-
gated methods.84 Nevertheless, the adjustable injection volume range of the 
utilized autosampler as well as the column capacity could be limiting factors of 
this method due to the widely varying creatinine concentrations of urine speci-
mens. For example, the creatinine concentrations in our small sample set of 50 
specimens varied by a factor of 37.1 from 0.9 – 33.4 mM, In another study, 
urine specimens were normalized to specific gravity, measured by a refractome-
ter, prior to LC/MS analysis.86 However, depending on the predominant solutes, 
e.g. salts, glucose or urea, present in urine, the refractometer readings can be 
influenced.6,98,99 Consequently, different diets of patients could influence the 
measurement of the specific gravity as well as certain clinical conditions, such 
as diabetes mellitus, nephrotic syndrome or saline diuresis.100,101 In 2011, Mat-
tarucchi et al. proposed a pre-acquisition normalization method applying 
MSTUS as a corrective factor for the dilution of the samples. Nonetheless, the 
MSTUS are affected by the precision and reproducibility of the peak picking 
process and missing values lower the efficacy of this normalization strategy.85      
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6.3.5 Classification of a second sample set 
To test robustness of sample classification based on feature integrals obtained 
for urinary specimens diluted to a uniform creatinine concentration, a RF-based 
classifier was trained on the data obtained in batch 3 and then tested with an 
independent test set (validation set 1, batch 4) that contained 25 additional NC 
and TREAT specimens each that were different from those of batch 3 (see Ta-
ble 6.1). The RF classification was performed one time. For the training set, the 
RF classifier obtained an overall classification accuracy of 96% with a corre-
sponding error rate of 4% for both groups. For the test set, the RF classifier ob-
tained an overall classification accuracy of 100% with a corresponding error rate 
of 0% for both groups. In order to exclude the possibility that the diagnostic ac-
curacies for these biological groups had been obtained by chance, permutation 
tests were performed 10 times. To achieve this, the class labels were randomly 
perturbed. For the training set, an averaged overall classification accuracy of 
45.0 (+/- 8.2)% with averaged error rates of 56.0 (+/- 9.8)% and 54.0 (+/- 7.6)%, 
respectively, for the NC and the TREAT group were obtained. The respective 
averaged overall classification accuracy for the test set was 44.8 (+/- 23.2)%, 
with respective averaged error rates of 56.0 (+/- 32.2)% and 54.4 (+/- 23.8)% for 
the NC and the TREAT group. The far lower classification accuracy of the per-
mutated data indicates that the results for the non-permutated data were with 
high probability not obtained by chance.  
Next, a comparison of NC versus TREAT samples was performed employing 
two-sided Welch t-statistics separately for training and test set, yielding 166 and 
226 significantly discriminant features with Benjamini-Hochberg-adjusted p-
values below 0.05, respectively. The number of discriminant features common 
to both training and test set was 130. Figure 6.9 displays a heat-map represen-
tation of these 130 features for both training and test data. The groups, each 
comprising 25 samples, were arranged from left to right: NC training set, NC 
test set, TREAT training set, and TREAT test set, while rows are ordered in cor-
relation with disease status. Figure 6.9 shows the homogeneity of the up and 
down regulation of the significantly different features within each group as well 
as the divergence between the groups. This emphasizes the diagnostic rele-
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vance of the detected metabolic features in the identification of patients with 
chronic kidney disease.  
 
Figure 6.9: Heat-map representation of the 130 features that distinguish healthy controls from 
patients with chronic kidney disease. Rows are ordered in correlation with disease status. Urine 
specimens of the first and second set were diluted to uniform creatinine concentrations of 1.5 
and 2.0 mM, respectively. The up- and down-regulation of features is color coded in yellow and 
blue, respectively. NC samples and TREAT samples are marked with a red and blue box, re-
spectively. Reprinted from Vogl et al. 2016.
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6.3.6 Feature identification 
We next attempted to assign metabolites to the N=130 discriminant features. It 
should be noted that each feature does not necessarily equal an individual me-
tabolite. Rather, metabolites, for example due to in-source fragmentation, may 
be represented by more than one feature. Therefore, we sorted features ac-
cording to retention time and grouped them. This resulted in 72 potential me-
tabolites, which were subjected to further identification as recently described.68 
Sum formulas were calculated using the Smart Formula tool (Bruker Daltonics). 
The calculated mass error in mDa and the mSigma value as a measure for the 
isotopic fit are listed in Table 11.1 (Appendix). The average mass error was be-
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low 1.5 mDa. Each feature was searched in the HMDB102, METLIN103 and 
ChEBI (Chemical Entities of Biological Interest) databases104, respectively, and 
wherever possible a tentative identification was made (Table 11.1, Appendix). 
Reference compounds were analyzed to verify the identification of 3-
methylhistidine, citric acid, uric acid, hypoxanthine, methyladenosine, 
methylxanthine, tryptophan, 1,7-dimethylxanthine, phenylalanine and hippuric 
acid. Among the identified metabolites, N-acetylcarnosine, citric acid, hypoxan-
thine, tryptophan, and hippuric acid, just to name a few, are metabolites that 
have been already associated with renal disease in the literature.12,105 
6.3.7 Analysis of an independent patient cohort 
To validate our results on an independent data set (validation set 2) and to ex-
clude the possibility that discrimination of CKD and healthy specimens was 
driven by factors other than renal disease and diabetes, such as differences in 
diet and life style between the multinational TREAT cohort and the German NC, 
we analyzed a set of 50 baseline urine specimens from the German CKD study 
that had been selected to represent patients with reduced GFR with and without 
diabetes and/or increased albuminuria, respectively. These and 25 urine speci-
mens from the NC cohort, which had already been analyzed before as part of 
batch 4, were diluted to a uniform creatinine concentration of 1 mM prior to LC-
HRTOFMS analysis (batch 5). Hierarchical cluster analysis yielded again dis-
tinct clusters for GCKD and NC (Figure 6.10). However, this time two apparently 
healthy NC samples (NC 39, 33) clustered within the GCKD cluster and a single 
GCKD (GCKD 8) sample clustered within the NC cluster. Nevertheless, the re-
sults clearly demonstrated once more the ability of LC-HRTOFMS based me-
tabolite fingerprinting to distinguish between urine specimens of healthy individ-
uals and those with CKD. 
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Figure 6.10: Hierarchical cluster analysis of fingerprinting data of an independent, more diverse 
sample cohort (GCKD, batch 5) employing the Manhattan distance as a distance measure. 
Samples were diluted to a fixed creatinine concentration of 1.0 mM before the measurement. 
GCKD and NC samples are marked with a blue and red box, respectively. Reprinted from Vogl 
et al. 2016.
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Next, the diagnostic accuracy for samples from patients with CKD of two inde-
pendent patient cohorts (TREAT and GCKD) was investigated. To that end, the 
25 TREAT and 25 NC samples from batch 3 (normalization set), the 25 TREAT 
and 25 NC samples from the independent test set (batch 4, validation set 1) and 
the samples from the independent patient cohort (50 GCKD and 25 NC sam-
ples, batch 5, validation set 2) were aligned to test different training and test 
sets with the RF classifier (see Table 11.2 A-H, Appendix). Prior to classifica-
tion, normal distribution of batches 3, 4 and 5 was verified by the Shapiro-Wilk 
test (batch 3: p=0.123, batch 4: p =0.248, batch 5: p=0.146). In order to correct 
for the different fixed creatinine concentrations to which batches 3, 4 and 5 were 
diluted to (1.5 mM, 2.0 mM, and 1.0 mM, respectively), the aligned bucket table 
was Quantile normalized and log2 transformed prior to further data analysis. In 
Figure 6.11, a hierarchical cluster analysis of the aligned batches (batch 3, 4 
and 5) is depicted.  
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Figure 6.11.  Hierarchical cluster analysis of the aligned data set of first and second sample set 
(TREAT and NC, batch 3, 4) and the independent patient cohort (GCKD and NC, batch 5) in-
cluding the NC samples measured within batch 5. Urine samples were diluted to uniform creati-
nine concentrations of 1.5 mM, 2.0 mM ,and 1.0 mM, respectively. TREAT/GCKD (diseased 
patients) and NC (apparently healthy) specimens are marked with a blue and red box, respec-
tively. Cluster branches of GCKD, TREAT and NC are colored green, red and blue, respectively. 
The R package dendextend and circlize was used for the visualization.
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 Reprinted from 
Vogl et al. 2016.
74
 
Three distinctive clusters were obtained corresponding to the three sample 
groups TREAT, GCKD and NC. While the TREAT cluster comprised TREAT 
samples only, the GCKD cluster contained in addition three NC samples (NC 2, 
6, 25) from apparently healthy individuals and a TREAT sample (TREAT 18). 
Two additional TREAT samples (TREAT 22, 29) clustered within the NC cluster. 
The distinct clusters observed for the TREAT and the GCKD indicates that fac-
tors other than a reduced glomerular filtration rate may distinguish the two CKD 
cohorts. 
Next, we used a RF classifier to classify samples into diseased and healthy. For 
this, the above bucket table consisting of batches 3, 4 and 5 was divided multi-
6. Evaluation of dilution and normalization strategies to correct for urinary output 
in HPLC-HRTOFMS metabolomics 
71 
 
ple times into different training and test sets as shown in Table 11.2 (Appendix). 
For the RF classification, duplicate NC samples measured independently within 
batch 4 and batch 5 were excluded either from the training or test set. The RF 
classification was performed three times per test (A-H). Mean values are shown 
for the prediction accuracies. Results are summarized in Table 11.2. Training 
the RF classifier on the data obtained in batch 5 and employing batch 4 and 5 
as test set (Test A, Table 11.2, Appendix) resulted in an overall classification 
accuracy of 92%, whereby the sensitivity (TREAT) and specificity (NC) amount-
ed to 100% and 75%, respectively. This result revealed that training the RF 
classifier on batch 5, which consisted of GCKD and NC patients, classified 
TREAT samples with perfect accuracy (100%). This also holds true for tests B 
and D where the predication accuracies for TREAT samples were 100% for 
both tests, whereas the prediction accuracies for NC samples were 75% and 
73%, respectively (Table 11.2).  For test F, batch 5 was split (Batch 5/2). One 
half was used together with batches 3 and 4 for training and the other half for 
testing.  Results revealed perfect predictions for both NC individuals and GCKD 
patients. In addition, the training set of test G used one half of batch 5 and 
batch 3 as training set whereas test H used batch 4 and one half of batch 5. 
Here again, perfect predictions of GCKD and TREAT samples were achieved. 
NC prediction accuracy was 82% for test G and 76% for test H, which led to an 
overall prediction accuracy of 92% (test G) and 90% (test H), respectively. 
However, for tests C and E, where training was based solely on NC and TREAT 
samples, inferior results were obtained for the prediction of GCKD samples. 
This clearly indicates that training data must include samples of this cohort to 
allow reliable classification of GCKD samples, as it was the case for tests F, G 
and H.  
Finally, a comparison of the discriminant features of GCKD versus NC (batch 5) 
and TREAT versus NC (batch 3 and batch 4) with Benjamini-Hochberg-adjusted 
p-values below 0.05 yielded 49 features common to both patient cohorts 
(TREAT and GCKD). The corresponding potential metabolites are marked in 
Table 11.1. This result further indicates that the metabolic profiles of both, the 
TREAT and the GCKD share metabolites whose abundance differs significantly 
from that in the urine of apparently healthy individuals. 
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6.4 Conclusions 
The present study demonstrates the advantages of pre-acquisition dilution of 
urine to a fixed creatinine concentration in the acquisition of metabolic finger-
prints by LC-MS. This was demonstrated by the absence of significant correla-
tions of MVs with either creatinine concentration or osmolality values. Moreover, 
this method yielded among all investigated approaches the highest percentage 
of significantly discriminant features between CKD and apparently healthy urine 
specimens. The second best method in terms of percentage of discriminant fea-
tures was uniform dilution in combination with post-acquisition normalization to 
the sum of all integrals. The superiority of pre-acquisition dilution to a uniform 
creatinine concentration was also evident from hierarchical cluster analysis, 
which reliably assigned the urine specimens of controls and CKD patients to 
their respective clusters. In contrast, the other dilution and normalization meth-
ods tested yielded indistinct clusters. Hence, uniform dilution (e.g. 1:4) in com-
bination with normalization to creatinine or osmolality, respectively, is not rec-
ommended. The analytical consequences of high variability in metabolite abun-
dance between samples, such as ion suppression, detector saturation and col-
umn overloading, are not sufficiently accounted for by these normalization 
methods. 
Furthermore, the proposed normalization method allows reliable sample classi-
fication as demonstrated for several different patient cohorts. Also, as demon-
strated for batches 3 and 4, metabolites corresponding to differential features 
were for the most part identified. The results obtained underscore the superior 
reproducibility and applicability of pre-acquisition dilution to a uniform creatinine 
concentration and, thus, justify the associated time and labor. 
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7. Development of a quantitative LC-QqQMS 
method for renal disease-associated metabolites 
7.1 Introduction 
The problematic nature of current kidney disease markers was already dis-
cussed in chapters 4.2 and 6. Shortly, serum creatinine, the most applied clini-
cal marker of renal dysfunction, rises only after 50% of kidney function is al-
ready lost. Moreover, the amount of tubular secretion of creatinine results in 
overestimation of renal function at lower glomerular filtration rates (GFR) and it 
reflects differences in muscle mass.8 Ideally, filtration markers for GFR estima-
tion should eliminate renal net reabsorption or secretion in the nephron.34  
In the search of better alternatives to the so far established kidney disease 
markers, Takahira et al. in 2001 showed that C-mannosyltryptophan (CMT) is a 
potential novel marker of renal function.108 Moreover, Yonemura et al. demon-
strated that CMT is a more reliable diagnostic parameter than serum creati-
nine.109 Furthermore, pseudouridine (PSU) was associated with renal decline 
and discussed as renal marker in several studies.110-112 Additionally, Sekula et 
al. showed in 2016 that CMT and PSU are strongly and reproducibly associated 
with eGFR and CKD in population-based studies.34 Therefore, a quantitative 
method was urgently needed for those markers in order to investigate the frac-
tional excretion (FE) of CMT and PSU and to obtain an accurate picture of their 
renal clearance (see also chapter 4.2). In more recent studies, such as the Co-
operative Health Research in the Region of Augsburg S4/F4 Study113, the 
Framingham Heart Study114, and the Atherosclerosis Risk in Communities 
Study115 the relation between baseline metabolite profiles and the subsequent 
progression of CKD was investigated. In all of these studies different tryptophan 
metabolites were associated with CKD.116 Therefore, the comprehensive study 
of tryptophan metabolites in urine appeared as highly promising in the search of 
kidney disease markers, which I addressed by the development of a quantita-
tive method for an extended panel of tryptophan metabolites.  
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In 2011, Zhu et al. published a comprehensive quantitative HPLC-MS based 
method for the determination of tryptophan metabolites.69 In the course of this 
thesis, the quantitative method from Zhu et al was combined with a newly im-
plemented quantitative HPLC-MS method for CMT, PSU as well as metabolites 
which were identified as discriminating metabolites between patients suffering 
from CKD and healthy controls within the evaluation of normalization strategies 
(see chapter 6). Amongst these are creatine (CRT), creatinine (CRE), hippuric 
acid (HIP), xanthine (XT), hypoxanthine (HX), uric acid (UA) and guanidinoace-
tate (GUA), methylxanthine (MX), and dimethylxanthine (DMX), all of which 
have been described previously in the literature as being associated with renal 
disease.32,117-120  
Preparation of standard solutions and IS solutions were carried out by Lisa 
Ellmann. Additionally, preparation of calibration curves and spike-in experi-
ments as well as manual recalibration of both was performed by Lisa Ellmann 
and Katja Dettmer-Wilde.  
7.2 Experimentals 
7.2.1 Chemicals  
Uric acid, 1-methyluric acid, 3-indoxyl-sulfate, 2,5-furandicarboxylic acid, crea-
tine, creatinine, hippuric acid, guanidinoacetic acid, hypoxanthine, methylxan-
thine, kynurenic acid, DL-kynurenine, DL-tryptophan, xanthurenic acid, 3-
hydroxyanthranilic acid, indole-3-acetic acid, 3,4-dihydroxy-L-phenylalanine, 
DL-indole-3-lactic acid, indole-3-propionic acid, indole-3-carboxaldehyde, in-
dole-3-pyruvic acid, tryptamine, tryptophol, nicotinic acid, melatonin, 3-hydroxy-
DL-kynurenine, 5-hydroxyindole-3-acetic acid, 1,7-dimethylxanthine, indole-3-
acetic-2-2-d2* acid, uric acid 15N*, methylxanthine 13C,D3* were purchased 
from Sigma Aldrich (Taufkirchen, Germany). Xanthine, ß-pseudouridine, nico-
tinamide, quinolinic acid, methylguanine, pseudouric acid 13C-15N*, indoxyl-
sulfate d4*, hippuric acid d5*, hypoxanthine 13C2,15N*, serotonine d4*, hy-
droxykynurenine, 1-methylinosine, tiglylcarnitine were purchased from Toronto 
Research Chemicals (Toronto, Canada). Anthranilic acid, serotonin hydrochlo-
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ride were ordered from Fluka (Munich, Germany). Creatinine d3*, 5-
hyroxyindole-3-acetic acid d5*, kynurenic-3,5,6,7,8-d5* acid, nicotinamide d4*, 
nicotinic acid d4*, tryptamine d4*, tryptophan d5* were purchased from CDN 
Isotopes (Quebec, Canada). C-mannosyltryptophan d4* was ordered at Santa 
Cruz (Heidelberg, Germany). C-mannosyltryptophan was kindly supplied by 
Shino Manabe (Synthetic Cellular Chemistry Laboratory Hirosawa, Japan). 3-
hydroxyanthranilic acid d3*, anthranilic acid d4*, kynurenine d4*, quinolinic acid 
d3* were purchased from Buchem (Apeldoorn, the Netherlands).  
7.2.2. Solutions 
Stock solutions of each internal standard were prepared in water with 0.1% (v/v) 
formic acid and stored at -80°C. The stable isotope labeled standards were 
combined in two different internal standard mixtures (IS-mix 1 and IS-mix). IS 
mix 1 contained all labeled internal standards from the tryptophan pathway and 
IS mix 2 contained all other labeled internal standards. These two IS-mixes 
were combined 1:1 to a IS master mix. In the IS master mix concentrations 
were 5 µM for the IS-mix 1 standards except quinolinic acid-d3 and tryptophan-
d5, which had a concentration of 50 µM and 100 µM, respectively. All IS from 
IS-mix 2 had a concentration of 50 µM. 
Stock solutions of each unlabeled standard were prepared in either water, 
methanol, water/methanol, water/formic acid 0.1% or water/ 1 M NaOH mixtures 
(for details see Tab 11.3, Appendix). Different solvents were used according to 
the solubility of the analytes. Formic acid 0.1% and 1 M NaOH were added only 
in necessary amounts. Three different analyte mixes (AM) were produced. AM 1 
contained all metabolites from the tryptophan pathway, AM 2 contained uremic 
toxins and AM 3 contained methylinosine, 1,7-dimethylxanthine, tiglylcarnitine 
and methylguanine (see Tab. 7.1, 7.2 and 7.3). Many of these metabolites were 
determined in chapter 6 as discriminating metabolites between patients with 
CKD and healthy volunteers. A master mix was generated from AM 1, AM 2 and 
AM 3. Therefore, 500 µL of AM 1 was mixed with 400 µL of AM 2 and 100 µL of 
AM 3. This master mix was serially diluted with 0.1 % formic acid covering 19 
points over a concentration range of 0.04-11,317 nM in AM 1 except for TRP 
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where the range was 0.42-110,799 nM, 0.69-180,198 nM in AM 2 except for 
CRE, where the range was 2.06-539,839 nM and 0.26-67,505 nM in AM 3.  
Table 7.1. Concentrations of metabolites included in analyte mix 1 (AM 1). 
AM 1 c [µM] 
Kynurenic acid 0.05 
DL-Kynurenine 0.05 
Nicotinamide  0.05 
DL-Tryptophan 0.50 
Xanthurenic acid 0.05 
Quinolinic acid 0.05 
Anthranilic acid 0.05 
3-Hydroxyantranilic acid 0.05 
3-Indoleacetic acid 0.05 
Serotonin  0.05 
DL-lndole-3-lactic acid 0.05 
Indole-3-propionic acid 0.05 
Indole-3-carboxaldehyde 0.05 
Indole-3-pyruvic acid 0.05 
Tryptamine 0.05 
Tryptophol 0.05 
Nicotinic acid  0.05 
Melatonin 0.05 
3-Hydroxy-DL-Kynurenine 0.05 
5-Hydroxyindole-3-acetic acid 0.05 
 
Table 7.2: Concentrations of metabolites included in analyte mix 2 (AM 2). 
 AM 2  c [µM] 
Uric acid 1000  
3-Indoxylsulfate 1000 
Creatine 1000   
Creatinine 3000  
ß-Pseudouridine 1000 
Hippuric acid 1000 
Guanidinoacetic acid 1000   
C-Mannosyltryptophan 1000 
Xanthine 1000 
Hypoxanthine 1000   
Methylxanthine 1000 
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Table 7.3: Concentrations of metabolites included in analyte mix 3 (AM 3). 
 AM 3 c [µM] 
1-Methylinosine 1500 
1,7-Dimethylxanthine 1500 
Tiglylcarnitine 1500 
Methylguanine 1500 
7.2.3 Sample preparation  
For calibration, 10 µL of the internal standard solution were transferred to a 96 
well plate with 0.5 mL wells (Agilent Technologies, Waldbronn, Germany) and 
then diluted to 100 µL with the respective aqueous calibration standard. The 
well plate was covered with a silicone closing mat for 96 well plates (Agilent 
Technologies).  
For the spike-in experiment, endogenous concentrations were determined be-
forehand for five different urine samples. Three urine samples from the GCKD 
study as well as two samples from apparently healthy volunteers were used. 
Urine samples were pre-diluted 1:5 with water (PURELAB Plus water). The 
urine samples from the volunteers were measured in replicates (N=18), where-
as for the GCKD samples single measurements were used. The mean of this 
concentration was used to calculate the concentrations of the metabolites for 
the spike-in mix which was then generated for urine. It contained all analytes in 
10-fold higher concentration than the endogenous urine concentration levels.  
For the actual spike in experiment, two urine samples from apparently healthy 
volunteers and two samples from patients with chronic kidney disease from the 
GCKD study were used (for detailed information see chapter 6.2.2).  In order to 
generate the spiked matrix samples with 1-fold of the endogenous concentra-
tion for the spike in experiments, 10 μL of IS-master mix were added to 10 μL of 
pre-diluted urine and 10 µL of the urine spike-in mix. Next, samples were diluted 
to a final volume of 100 μL with water. The spike-in experiment was performed 
in a 96 well plate with 0.5 ml wells (Agilent) covered with a silicone closing mat 
for 96 well plates (Agilent). 
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As calibration check sample the master mix solution (AM 1, AM 2 and AM 3) 
was diluted 1:50 with 0.1% formic acid. Then 10 µL internal standard solution 
was added to 90µl of this diluted master mix dilution.  
7.2.4 Instrumentation 
An Agilent 1200 SL HPLC system (Böblingen, Germany) coupled to a 4000 
QTrap mass spectrometer with a TurboV electrospray ion source (Sciex, Darm-
stadt, Germany) was utilized. MS parameters were optimized using direct infu-
sion. The ion source was operated employing the following specifications: turbo 
ion spray voltage 5,500 or -4,500 V, curtain gas 10 psig, ion source temperature 
500 °C, ion source gas 1 and 2 at 50 psig, collision gas medium. Measurements 
were performed in positive and negative ionization mode and multiple reaction 
monitoring applying the parameters summarized in Tab. 7.4. Spike in experi-
ments were measured in both positive and negative ionization mode.  
Chromatographic separation was performed using an Atlantis T3 (2.1×150 mm 
i.d, 3 μm, Waters, Eschborn, Germany) reversed-phase column equipped with a 
C18 security guard column (Phenomenex, Aschaffenburg, Germany). Elution 
was carried out by gradient elution with mobile phases A (0.1% formic acid in 
water, v/v) and mobile phase B (0.1% formic acid in acetonitrile, v/v) with the 
following gradient: from 0% to 40% B in 10 min, 40% to 95% B in 2 min (10-12 
min) and from 12.0 to 12.1 min 0% B, which was hold for 4.9 min. The column 
temperature was 30°C and an injection volume of 10 μL was used. Samples 
were measured randomized. After 20 samples a urine reference sample from a 
healthy volunteer and the calibration check sample were measured. 
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Table 7.4: List of applied MRM parameters, DP (declustering potential), CE (collusion energy) 
and CXP (collusion cell exit potential) for each analyte measured. a) Metabolites newly added to 
the method of Zhu et al.
69
 b) Metabolites included within the method of Zhu et al.
69
  
Analyte Ab-
brevi-
ation 
Q1 
mass 
Q3 
mass 
DP CE CXP 
Period1       
Creatininea CRE 114.0 86.0 26 17 14 
Creatinine D3  117.0 89.0 26 17 14 
Guanidinoacetatea GUA 117.0 43.0 36 35 8 
Nicotineamideb, NAM 123.0 80.0 46 31 4 
NAM D4  127.0 84.0 46 31 4 
Nicotinic acidb NA 124.0 80.0 56 31 12 
NA D4  128.0 84.0 56 31 12 
Creatinea CRT 132.2 90.0 21 19 14 
Hypoxanthinea HX 137.1 110.3 66 33 6 
Hypoxanthine-13C,15N  139.1 112.3 66 33 6 
Methylguaninea MG 166.0 149.0 66 27 8 
Quinolinic acidb QA 168.0 149.9 41 15 12 
Quinolinic acid D3  171.0 153.0 41 15 12 
Hydroxykynurenineb HK 225.2 208.0 41 13 12 
Hydroxikynurenine D3  228.2 211.0 41 13 12 
Pseudouridinea PSU 245.1 209.1 20 15 10 
Pseudouridine 13C15N1  248.1 212.1 20 15 10 
       
Period 2       
Xanthinea XT 153.0 136.0 86 21 6 
Methylxanthinea MX 167.2 110.2 60 52 9 
Methylxanthine-13C,D3  171.2 110.2 60 52 9 
Serotoninb SER 177.2 160.1 41 15 12 
Serotonin D4  181.1 164.0 41 15 12 
Kynurenineb KYN 209.1 192.0 40 13 14 
Kynurenine D4  213.1 196.0 40 13 14 
1-Methylinosinea MI 283.1 151.0 40 19 12 
C-Mannosyltryptophana CMT 367.2 156.2 61 47 18 
C-Mannosyltryptophan D4  371.2 160.2 61 47 18 
       
Period 3       
Hydroxianthranilic acidb HAA 154.2 80.0 46 36 14 
Hydroxianthranilic acid D2  156.2 82.0 46 36 14 
Tryptamineb TRY 161.0 144.0 36 15 12 
Tryptamine D4  165.0 148.0 36 15 12 
Hippuric acida HIP 180.1 105.0 46 23 2 
Hippuric acid D5  185.1 110.1 46 23 2 
Dimethylxanthinea DMX 181.1 124.1 41 29 20 
Dimethylxanthine-D6  187.1 127.1 41 29 20 
Kynurenic acidb KA 190.2 144.0 51 30 10 
Kynurenic acid D5  195.2 149.0 51 30 10 
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Hydroxyindolacetic acidb HIAA 192.2 146.0 31 21 10 
Hydroxyindolacetic acid D5  197.2 151.0 31 21 10 
Tryptophanb TRP 205.1 118.1 39 26 11 
Tryptophan D5  210.2 122.0 39 26 11 
Xanthurenic acidb XA 206.2 160.0 56 27 10 
Tiglylcarnitinea TG 244.1 84.9 56 27 6 
       
Period 4       
Anthranilic acidb AA 138.2 120.0 36 15 8 
Anthranilic acid D4  142.1 124.0 36 15 8 
Indol3-carboxaldehydeb INC 146.2 118.2 51 21 8 
Tryptopholb TPO 162.2 115.0 51 41 6 
Indole-3-acetic acidb IAA 176.2 130.0 56 25 8 
Indole-3-acetic acid D2  178.2 132.0 56 25 8 
Indole-3-propionic acidb IPA 190.2 130.1 51 22 8 
Indole-3-lactic acidb ILA 206.2 130.0 36 39 8 
Melatoninb MEL 233.1 174.0 56 21 14 
Melatonin D4  237.1 178.0 56 21 14 
       
Negative ion mode       
3-Indoxylsulfate IS 212.0 80.0 -60 -30 -11 
3-Indoxylsulfate-D4  216.0 80.0 -60 -30 -11 
Uric acida UA 167.1 124.0 -65 -20 -19 
Uric acid-15N2  169.1 125.1 -65 -20 -19 
 
7.3 Method validation 
7.3.1 Quantification  
For GUA, CRT, MG, XT, MI and TG, no stable isotope labeled standards were 
available. Therefore, stable isotope labeled standards eluting nearby were ap-
plied for calculating the respective area ratios. For GUA and CRT, CRE D3 was 
used, for MG hypoxanthine-13C,15N, for XT and MI methylxanthine-13C,d3, for 
TG 1,7-dimethylxanthine-d6, for XA KA-d5, for ILA, IPA, melatonin and tryp-
tophol IAA-d2. This assignment was based on chemical and retention time simi-
larity.  
Quantification was performed using the respective stable isotope labeled inter-
nal standards. Data analysis was carried out using Analyst version 1.6.2 (Sci-
ex). 
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7.3.2 Linear range, LOD and LOQ 
The method was validated testing linearity, limit of detection and quantification, 
recovery and precision. The linear range described by the lower and upper limit 
of quantification (LLOQ and ULOQ, respectively) was assessed for each ana-
lyte. The LLOQ and the ULOQ are the lowest and the highest concentration for 
which quantification can be performed with a certain precision and trueness. 
According to the FDA Guide for Bioanalytical Method Validation73, the LLOQ 
and the ULOQ are defined as the lowest and highest points of the calibration 
curve which can be quantified with accuracy between 80% and 120% and an 
imprecision smaller than 15%, except at the LLOQ where it should be smaller 
than 20%. Therefore, a series of standard solution accompanied by the respec-
tive internal standards was used. Each standard solution was measured at least 
one time. Nine standard solutions of the linear dilution series (calibration points 
3, 5, 7, 9, 11, 13, 14, 17, 19) were measured three times in order to assess the 
precision over the calibration range. The limit of detection (LOD) is the lowest 
detected concentration which is detectable but not necessarily quantified. The 
LODs were determined from the linearity data as a signal to noise ratio (S/N) of 
≥3.  
7.3.3 Recovery and precision 
Analyte recovery and precision for the analysis of urine were determined using 
a standard working solution of all candidates that was spiked into aliquots of 
urine. In order to determine the spike concentration for each metabolite, four 
urine samples were first measured unspiked with 10 µL injection volumes. The 
mean endogenous concentration for each metabolite was calculated. Then, a 
standard solution was added that contained the analytes at the initially deter-
mined endogenous urine concentration levels resulting in a 1-fold increase of 
the analyte concentrations. This was performed in triplicate for four different 
urine samples with an injection volume of 10 L (spike-in experiment).  
In order to determine the analyte concentration for the spiked urine the respec-
tive calibration curves were applied. Then, the endogenous concentration of the 
analyte, which was determined in the unspiked sample, was added to the theo-
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retical spike concentration (desired value), which was determined beforehand. 
Finally the ratio between the measured spiked concentration (actual value) and 
this sum was calculated and expressed as recovery in percent (see following 
equation).  
 
(
𝑐𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑(𝑠𝑝𝑖𝑘𝑒𝑑 𝑎𝑛𝑎𝑙𝑦𝑡𝑒)
(𝑐𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑(𝑢𝑛𝑠𝑝𝑖𝑘𝑒𝑑 𝑎𝑛𝑎𝑙𝑦𝑡𝑒) + 𝑐𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑(𝑠𝑝𝑖𝑘𝑒𝑑 𝑎𝑛𝑎𝑙𝑦𝑡𝑒))
)  𝑥 100% 
 
7.4 Results and Discussion  
7.4.1 Chromatographic separation and MS detection of analytes 
The mobile phase and the gradient were adopted from Zhu et al..69 Due to the 
large number of metabolites baseline separation was not feasible for all me-
tabolites. It was a compromise between short analysis time and baseline sepa-
ration. This method was intended to be used for high throughput analysis there-
fore a short analysis time was essential. Consequently, baseline separation of 
all included metabolites is almost impossible within the applied gradient of 15 
min. In part, chemical structures and retention behaviors of the included metab-
olites are too similar. However, stable isotope labeled IS were used in order to 
minimize ion-suppression for co-eluting metabolites. The following metabolites 
co-elute (see Fig.7.1 and Fig. 7.2.): CRE, GA and CRT; NA, PSU, NAM and 
QA; MG, HX and HK; KYN and CMT; MI and MX; TG, TRP, DMX, TRY and XA; 
HIAA and HIP; MEL and INC; IAA and TPO. However, all these metabolites 
have different mass transitions. Therefore, the quantification is not affected by 
interferences.  
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Figure 7.1.: TIC of a LC-QqQ-MS measurement of a representative standard mix in positive 
ionization mode. Bold lines represent scan periods. 
The chromatographic run was divided into 4 scan periods in positive ionization 
mode (see Fig. 7.1 and Fig. 7.2). Thus, minimizing the number of transitions 
monitored in parallel. This resulted in 10-19 transitions per period. 
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Figure 7.2: XIC of a LC-QqQ-MS measurement of a representative standard mix in positive 
ionization mode. A: scan period 1, B: scan period 2, C: scan period 3 and C: scan period 4.  
Constancy of retention times for all analytes was checked for 100 urine samples 
from apparently healthy volunteers from the national cohort study (detailed de-
scription of this cohort see chapter 6.2.2). However, some metabolites were not 
detected in all samples. In Tab 7.5 the retention times are summarized for all 
metabolites measured in positive and negative mode. The RSD of retention 
times were below 1.3% for all analytes in both ionization modes. Small devia-
tions in RT can be due to contamination buildup or general column deteriora-
tion. Therefore, RT may drift for samples measured over a long period.  
For the calibration curves as well as for quantification, stable isotope labeled 
standards were used. As the stable isotope labeled standard will experience ion 
suppression in the same way as the respective endogenous analyte it will cor-
rect for ion suppression and accurate quantification should be achieved. Since 
several corresponding stable-isotope labeled standards were not available, data 
can only be used as semi-quantitative measures rather than quantitative 
measures because of the lack of an appropriate internal standard to correct for 
ion suppression. 
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UA and IS were measured in negative ionization mode because these metabo-
lites only were ionizable in negative mode. Consequently, one scan period for 
both analytes was sufficient (see Fig 7.3).  
 
Figure 7.3: XIC of a LC-QqQ-MS measurement of a representative standard mix in negative 
ionization mode. 
7.4.2 Calibration 
The quality of the calibration curves depends on the instrument status. For in-
stance, contamination of the MS instrument may result in higher background 
and/or lower signal intensities and a concomitant increase in LOD values. Fur-
thermore, column aging may negatively affect peak shapes and hence the 
quality of the calibration curves. Therefore, calibration curves need to be meas-
ured regularly or better before every measurement. Moreover, calibration 
curves need to be adapted to the concentration range of the metabolites in the 
matrix under investigation. Calibration curves were determined for each me-
tabolite, whereby a 1/x weighting was applied. In Tab. 7.5 calibration results are 
summarized.  
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Table 7.5: Calibration parameters.  
Analyte RT 
(min) 
LOD 
(nM) 
Linear range 
(nM) 
Slope Intercept R2 OOM 
GUA 1.05 0.686 5.49-45000 0.44 0.0111 0.9998 4 
 CRE 1.06 2.06 65.9-270000 0.96 0.0074 0.9995 4 
CRT 1.19 0.684 700-44800 7.29 0.6650 0.9987 2 
NA 2.12 0.687 0.687-2810 0.91 0.0011 0.9997 4 
PSU 2.33 0.684 1.37-44800 0.57 0.0003 0.9991 4 
NAM 2.44 0.687 2.75-2810 3.01 0.0057 0.9988 3 
QA 2.80 11.1 11.1-11300 0.93 0.0010 0.9998 3 
MG 3.29 0.257 2.06-527 142 0.0222 0.9969 2 
HX 3.45 2.75 87.8-22500 18 0.1460 0.9977 3 
XT 4.69 0.687 1.38-90100 2.38 0.0129 0.9995 4 
SER 5.70 0.043 0.343-1410 1.12 0.0002 0.9990 4 
KYN 6.05 0.043 1.37-2810 1.21 0.0023 0.9986 3 
CMT 6.17 0.687 2.75-11300 0.52 0.0001 0.9982 4 
MI 6.45 0.257 1.03-132 63.2 0.0028 0.9950 2 
MX 6.48 1.38 11.0-45000 0.26 0.0001 0.9997 3 
HAA 7.09 0.043 2.75-5630 0.63 0.0148 0.9990 3 
TRP 7.49 1.69 6.76-13800 1.62 0.0009 0.9977 4 
TG 7.50 0.258 527-4220 3.37 0.8170 0.9877 1 
DMX 7.64 0.515 1.03-2110 0.98 0.00003 0.9983 3 
TRY 7.67 0.086 0.686-702 0.64 0.0003 0.9975 3 
XA 8.20 0.344 22-2820 0.71 0.0194 0.9987 2 
KA 8.65 0.086 2.75-704 1.19 0.0004 0.9989 2 
HIAA 8.87 0.344 2.75-2820 4.43 0.0040 0.9990 3 
HIP 9.07 2.75 11.0-1410 1.30 0.0010 0.9985 2 
AA 10.16 0.345 0.345-353 0.93 0.0009 0.9995 3 
ILA 11.27 1.37 1.37-5620 0.23 0.0002 0.9996 3 
INC 11.81 0.043 0.172-176 3.57 0.0013 0.9977 3 
MEL 11.90 0.043 0.0430-44.0 23.10 0.0002 0.9987 3 
IAA 12.40 0.172 0.344-1410 1.02 0.0005 0.9987 4 
TPO 12.41 1.37 2.75-5620 0.13 0.0005 0.9999 3 
IPA 13.60 0.172 0.172-2810 0.94 0.0004 0.9997 4 
Nega-
tive 
mode 
       
 IS 9.27 0.687 11.0-11300 0.65 0.0007 0.9991 3 
UA 4.72 0.687 176-45000 1.57 0.3970 0.9992 2 
 
The LLOQ ranged from 0.04 nM to 11.0 nM for most metabolites except for 
CRE, CRT, HX and XA with an LLOQ of 65.9 nM, 700 nM, 87.8 nM and 22.0 
nM, respectively. Most metabolites had an ULOQ of 44.0 nM to 90.0 µM only for 
CRE the ULOQ ranged up to 270 µM. For the two metabolites measured in 
negative mode, IS and UA, the linear range reached from 11.0 nM to 11.3 µM 
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and from 176 nM to 45.0 µM, respectively. For all analytes the R2 value of the 
regression analysis over the linear range was bigger than 0.99. Order of magni-
tudes (OOM) for all metabolites ranged between 1 and 4.  
RSDs of triplicate measurements of the nine selected standard solutions which 
were within the respective linear range were below 20% for all metabolites.  
The LOD of the metabolites measured in positive ionization mode ranged be-
tween 0.043 and 2.75 nM only QA had a LOD of 11.1 nM. The LOD of UA and 
IS was 0.687 nM for both.  
In comparison to the values Zhu et al. 2011 reported for the linear range of the 
tryptophan metabolites, the values here are similar, with some metabolites hav-
ing smaller LLOQ but also smaller ULOQ.69 For example, Zhu et al determined 
for TRP a linear range of 50-200,000 nM, whereas a linear range of 6.76-13800 
nM was found here. For other metabolites, e.g. KYN and XA, the linear range 
was narrower (1.0-7500 nM and 1.0-5000 nM, respectively). As mentioned 
above small variances can be explained by a different instrument status. How-
ever, one should keep in mind that the implemented method in positive mode 
includes more metabolites than the original method. Because more transitions 
per period were measured, MS dwell time had to be reduced for each transition 
to a greater extent than for the original method. This explains in part the more 
narrow linear ranges. Moreover, the final concentration of the IS differed for the 
two methods (see Tab. 7.6). This could also explain in part the differences in 
linear range.  
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Table 7.6. Comparison of internal standard (IS) concentration, linear range and order of magni-
tude (OOM) of the extended quantitative LC-QqQ-MS method and the original method imple-
mented by Zhu et al. in 2011.For all other ISs not mentioned in the table, Zhu et al. used a yeast 
extract for which no exact IS concentrations were available. 
 Extended method Original method (Zhu et al.) 
Analyte IS 
conc. 
(nM) 
Linear range 
(nM) 
OOM IS 
conc. 
(nM) 
Linear 
range 
(nM) 
OOM 
NA 500 0.687-2810 4 1000 5.0-10000 4 
NAM 500 2.75-2810 3 1000 1.0-10000 4 
SER 500 0.343-1410 4 200 1.0-4000 3 
TRY 500 0.686-702 3 200 0.5-1000 4 
HIAA 500 2.75-2820 3 1000 5.0-10000 4 
AA 500 0.345-353 3 200 1.0-1000 3 
 
7.4.3 Spiking experiment 
Mean recoveries of the spike in level for a subset of the 36 included metabolites 
were determined in urine. Four urine samples (2GCKD and 2 apparently healthy 
volunteers) were measured in triplicates. CMT, PSU, XT, HX, GA, MX, XA and 
TRP were analyzed in positive mode, UA and IS in negative ionization mode. 
These are metabolites newly included within the original method of Zhu et al.. 
TRP was selected because of its key role in the tryptophan pathway. Moreover, 
XA is an interesting metabolite also from the tryptophan pathway. UA and IS 
were the only measured metabolites in negative ionization mode. The other me-
tabolites newly added in positive ionization mode were either below LLOQ or 
above ULOQ.  
Results are depicted in Fig. 7.4 and Table 7.7. In urine, the selected metabolites 
(positive mode) showed mean recoveries over all 4 urine samples between 86-
121%, which indicates a very good recovery. RSD values ranged between 2% 
and 7%. This represents good repeatability of the spike-in experiments. For XA, 
only three (1 GCKD and 2 apparently healthy volunteers) of the four urine sam-
ples were in the linear range. A recovery of 89% with a RSD of 5.3% was ob-
tained for the spike-in experiment of these samples.  
7. Development of a quantitative LC-QqQMS method for renal disease-
associated metabolites 
89 
 
 
Figure 7.4: Mean recoveries ± SD over four samples of the spike-in experiment of the selected 
metabolites in urine. The black solid lines represent mean recoveries of 80% and 120%, respec-
tively (triplicate measurements of each sample).* For XA only three (1 GCKD and 2 apparently 
healthy volunteers) and for UA only two (one GCKD sample) of the four urine samples were in 
the linear range and were analyzed. 
 
Table 7.7: Mean recoveries and respective RSD values over four urine samples of the selected 
subset of metabolites from the spike-in experiments (N=3). 
 PSU GUA HX XT MX CMT TRP IS UA 
Mean  
recovery  
[%] 
114.1 97.9 108.0 105.2 94.3 120.5 85.7 84.9 96.6 
RSD [%] 5.8 5.9 4.7 2.0 4.4 5.2 7.2 3.5 0.0 
 
For UA the concentrations of all the reference samples and one GCKD sample 
were above the ULOQ. However, for 2 GCKD samples the spike-in yielded a 
recovery of 96.6%. For IS the recovery over all urine samples (2 GCKD and 2 
reference samples) was 85% (RSD 3.5%). Therefore, for both metabolites 
measured in negative ionization mode recoveries were very good. 
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In order to check the quality of the measurements, calibration check samples as 
well as reference samples were measured every 20 measurements. Accuracies 
of the calibration check measurements ranged between 95% and 111% except 
for CMT, which had a slightly increased accuracy (123%). RSDs of the refer-
ence samples ranged between 1.1 and 5.6% for the selected metabolites. 
These results imply the good quality of the method. 
In order to validate the metabolites, which exceeded the ULOQ or were below 
the LLOQ in the spiked samples, additional lower and higher spike-in levels 
would be necessary. Moreover, according to the FDA more urine samples as 
well as more replicates would be necessary. However, obtained recoveries for 
the selected subset were very good. Moreover, for creatinine and creatine a 
comparison with independent quantification methods (NMR and enzymatic as-
say) yielded a very good agreement for the CRE and CRT quantification (see 
7.4.4). Therefore, for these metabolites the implemented method is highly feasi-
ble for the analysis of urine samples.  
7.4.4 Application 
 
The developed method was applied to the targeted analysis of CRE, PSU and 
CMT in plasma and urine specimens collected by the Qatar Metabolomics 
Study on Diabetes (QMDiab) (n=111) and the GCKD study (n=328), respective-
ly.44 These measurements were part of a study published in Scientific Reports 
by Sekula et al. in 2017.44 In this study, CMT and PSU were investigated in de-
tail as potential kidney function markers and CRE was used for normalization of 
urine samples as well as for the calculation of the fractional excretion. 
The quality of measurements was stringently controlled via several reference 
samples, calibration check samples and blank samples, which were measured 
every 20 samples. As reference samples, a urine and serum sample were used 
for the QMDiab study, whereas a urine and plasma sample were used for the 
GCKD study.44  
Due to the study sizes, samples were measured in several batches using six 
sample plates for the GCKD and three plates for the QMDiab. Intra- and inter-
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batch variability were checked for the reference samples. In urine samples from 
the GCKD and QMDiab, the overall RSD of the reference measurements were 
below 8.9% for CRE, PSU and CMT. In the plasma samples from the GCKD 
study, the overall RSD values for CRE and PSU were below 18.5%. CMT was 
not detected in the plasma reference sample. However, the pooled human male 
plasma sample used as reference (purchased form Sigma-Aldrich/Fluka 
Taufkirchen, Germany) showed very low concentrations for all metabolites in 
comparison to CKD samples. In the serum reference samples measured within 
the samples of the QMDiab study, the overall RSD was below 15.3%.44 
Ranges of metabolite quantification and measures of quality (accuracy, coeffi-
cients of variations) per study population as well as batch-related intra-/inter-
variability in reference measurements are provided in Tables 7.8 and 7.9.44 Per 
study population and metabolite, accuracy of measurements was in the range of 
80% to 120%.44 All measurements were within the range of quantification. Coef-
ficients of variation were < 20% for all measurements except for PSU in plasma 
of GCKD participants (20.8%).44 These results demonstrate the excellent quality 
of the developed method in different matrices. 
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Table 7.8. Information of targeted measurements adapted from the paper of Sekula et al. 
2017.
44
 Targeted measurements were performed using the implemented quantitative method 
described in this chapter. Reprinted from Sekula et al. 2017.
44
 
 
 Plasma Urine 
Mode Accu-
racy 
CV ROQ* Mode Accu-
racy 
CV ROQ* 
QMDiab 
Creatinine + 98.5% 1.4 0.055-
900 
+ 98.3% 2.2 1.375-
22,500 
C-
mannosyltryptophan 
+ 94.4% 2.4 0.0274
-450 
+ 93.8% 1.9 0.685-
11,250 
Pseudouridine + 99.2% 6.9 0.055-
900 
+ 114.1% 4.5 1.375-
22,500 
GCKD 
Creatinine + 95.5% 5.4 0.0658
- 1,080 
+ 88.7% 3.6 3.295-
27,000 
C-
mannosyltryptophan 
+ 95.8% 11.8 0.0440
- 360 
+ 97.3% 7.7 0.2745-
9,000 
Pseudouridine + 86.9% 20.8 0.0109
-179.2 
+ 89.6% 10.
0 
0.1365-
1,120 
* unit: µmol/L (transformed limits: for plasma: *2/1000, for urine: *50/1000)  
CV: coefficient of variation; ROQ: range of quantification 
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Table 7.9: Intra- and inter-batch variability of targeted measurements of reference samples 
(adapted from the paper of Sekula et al 2017).
69
 Targeted measurements were performed using 
the quantitative method described in this chapter. Reprinted from Sekula et al. 2017.
44
 
Relative Standard  
Deviation (RSD) Batch Creatinine 
Pseudo- 
uridine 
C-mannosyl-
tryptophan 
QMDiab 
Urine reference 1 1.36 8.36 5.78 
2 1.86 7.06 2.63 
3 -* -* -* 
Overall† 2.41 7.03 6.02 
Serum reference 1 1.66 3.11 6.79 
2 -* -* -* 
3 2.28 7.15 - 
Overall† 1.7 7.2 15.27 
GCKD 
Urine reference,  
male 
1 1.1 11,2 4,7 
2 -* -* -* 
3 3.9 9.0 2.3 
4 3.7 8.6 3.8 
5 2 5.8 2.8 
6 -* -* -* 
Overall† 3.4 8.3 7.8 
Urine reference,  
female 
1 2.4 2.3 1.7 
2 -* -* -* 
3 3.5 6.1 6.9 
4 6.4 8.5 8.3 
5 1.8 8.2 3.6 
6 -* -* -* 
Overall† 3.9 8.7 8.9 
Plasma reference 1 7.4 14.0 -‡ 
2 4.5 10.9 -‡ 
3 3.4 12.1 -‡ 
4 1.7 4.5 -‡ 
5 -* -* -‡ 
Overall† 7.0 18.5 -‡ 
Overall, measurements were done on 6 plates for GCKD and on 3 plates for QMDiab.  
* Batch variability is not presented for plates with <3 reference measurements.  
† RSD calculation based on all reference measurements. 
‡ No reference values for C-mannosyltryptophan in plasma available as the measurements were at the LLOQ. 
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The developed quantitative method was also used in Wallmeier et al. (2017).121 
In this study, quantification of metabolites by NMR in the presence of protein 
were investigated. In order to validate the NMR measurements of CRE and 
CRT in plasma samples from patients with CKD, these samples were also 
measured by the LC-MS/MS method. Moreover, the CRE values of both the 
NMR and LC-MS/MS measurements were compared to an enzymatic CRE as-
say performed by a commercial clinical chemistry laboratory (Synlab GmbH, 
Augsburg, Germany). For the comparison of CRE values, 50 samples from the 
GCKD study were taken. The Bland−Altman plot revealed for the LC−MS/MS 
data slightly higher values with a mean difference of 10.5 μmol/L and 95% con-
fidence intervals of 38.5 and−17.4 μmol/L, respectively. The mean difference 
between LC-MS/MS and NMR was 12.0 µmol/L. Moreover, the mean difference 
in CRE values obtained by LC-MS/MS and the enzymatic assay was 1.1 µmol/L 
with 95% limits of agreement ranging from 14.9 to.17.1 µmol/L. Additionally, the 
comparison of CRT values showed a good agreement with the NMR measure-
ments demonstrated by a Bland-Altman plot with a mean difference of −1.37 
μmol/L with 95% limits of agreement ranging from +11.1 to −13.8μmol/L. These 
results demonstrate an excellent agreement between the LC-MS/MS method 
and the enzymatic assay and a good agreement with the NMR 
measurements.121 These findings demonstrated the quality of the developed 
quantitative LC-MS/MS method for CRE and CRT.  
7.5  Conclusions 
An LC-QqQMS method for the quantification of metabolites currently associated 
with renal disease was established. Therefore, the method established by Zhu 
et al. in 2011 was merged with a newly established method for metabolites cur-
rently associated with renal disease. The dynamic range of the merged method 
showed adequate sensitivity of all metabolites included for the analysis of urine 
samples.  
Further, a spike-in experiment showed very good recoveries for a subset of me-
tabolites. Moreover, several published applications proved the efficiency of the 
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implemented quantitative method in urine and plasma matrices for selected me-
tabolites. 
However, further experiments are necessary in order to validate all the metabo-
lites included in this method. Nevertheless, the presented results demonstrate 
the high potential of this method regarding the quantification of various metabo-
lites in urine from CKD patients. The combined HPLC-QqQMS-based targeted 
method enables the parallel quantitative investigation of tryptophan metabolites 
and other interesting metabolites associated with renal disease.117 Additionally, 
the method could shed new insights into the underlying pathophysiological 
mechanisms of CKD. 
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8. Comparison of fingerprinting LC-HRTOF-MS 
and LC-QqQMS profiling data  
8.1 Introduction 
The triple quadrupole mass spectrometer in multiple reaction monitoring (MRM) 
mode is the well-established gold standard for quantification of small molecules 
and metabolites. For quantification via qTOF-MS in MS/MS mode using stable 
isotope labeled internal standards, comparability to classical targeted analysis 
has already been demonstrated by several publications, e.g. Park et al. 2016.122 
However, for this technique a preselection of metabolites is necessary, limited 
by the availability of stable isotope labeled standards. Yet, recent instrumental 
improvements raise the question whether quantification in untargeted full scan 
mode using a quadrupole time-of-flight-mass spectrometer (qTOF-MS) is relia-
ble enough to replace targeted quantification in some cases.13,123  
Untargeted screening measurements result in semi-quantitative data while tar-
geted analysis yields absolute quantitative data. However, the reliability of 
quantitative data is dependent on the applied calibration method. For example, 
multi-point calibration using external calibration standards which are normalized 
by stable isotope labeled analogues is surely more reliable than a single-point 
calibration. Although, single-point calibration using a stable isotope labeled ana-
logue certainly is more reliable than using non-similar IS.123  
One tremendous advance of untargeted analysis is the parallel detection of 
thousands of metabolites with high resolution and mass accuracy. Instead, tar-
geted analysis is limited to detect only several hundreds of metabolites in paral-
lel.124,125 For certain applications the limited number of metabolites that can be 
simultaneously quantified in MRM mode is insufficient. Hence, quantification in 
full scan untargeted mode is a valuable alternative.126 The advantages of untar-
geted analysis in full scan mode make it highly interesting to investigate this 
technique for its quantitative performance.13,127 
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However, current knowledge about the performance of quantification in full scan 
mode, also called untargeted screening, in biological matrices is rather limited in 
comparison to the targeted quantification by MRM mode.  
In 2008 Lu et al. conducted such a comparison between a triple quadrupole in-
strument in MRM mode and a TOF-MS in full scan mode for 20 standard com-
pounds (10 in positive ion mode, 10 in negative ion mode) at 5 different concen-
tration levels, including a cellular extract.13 The published results were however 
limited to one standard compound.  
Similarly, in 2011 Ramanathan conducted a comparison of a hybrid QTOF 
mass spectrometer with a triple quadrupole MS/MS system.127 The comparison 
was performed with calibration curves for 25 metabolites including the drugs 
buspirone, prednisolone, prednisone, nefazodone and reserpine. The molecular 
weights of the compounds ranged from 230 to 747 Da.127 After protein precipita-
tion a drug free human plasma sample was spiked with these 25 metabolites in 
order to generate calibration curves ranging from 0.1 to 2000 ng/ml plasma. As 
internal standards, stable-isotope labeled (SIL) compounds and appropriate 
structural analogues were used. In addition to the full scan mode, the calibration 
curves also analyzed by LC-HRMS in information-dependent acquisition (IDA) 
MS/MS scan mode. Similar LOQs and linear ranges for the measurements of 
the samples with the combined TOF-MS and TOF-MS/MS (2 MS/MS scans). 
For the most part, the LLOQ was similar or better than the SRM mode.127 More-
over, they yielded a similar range to the SRM mode while the % CV and %bias 
were acceptable for the HRMS analysis.127 However, these results surely de-
pendent on the selected instruments.   
Recently, only few other papers further investigated the quantitative perfor-
mance of targeted versus untargeted LCMS analysis.128-133 Suhre et al com-
pared three different metabolomics platforms, Biocrates Life Sciences AG (Aus-
tria), Chenomx Inc. (Canada), and Metabolon Inc. (USA) for diabetes research. 
They used 100 blood samples from the KORA study (Cooperative Health Re-
search in the Region of Augsburg) consisting of 40 diabetes and 60 control 
samples for the investigation by all three platforms. Biocrates and Metabolon 
provided MS-based analysis, whereas Chenomx used a NMR-based analysis 
method. Moreover, Biocrates used a targeted MRM approach, while Metabolon 
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used an untargeted approach combining GC and LC chromatography. The final 
data set consisted of 482 distinct values of absolute (Biocrates and Chenomx) 
or relative (Metabolon) metabolite concentrations. Hereof, 68 metabolites could 
be quantified by two different platforms. These duplicate measurements yielded 
a median correlation coefficient (R) of 0.61, with the best results showing strong 
correlations up to R = 0.95. Suhre et al concluded that these results show the 
possibility for cross-platform replication.128  
Yet et al. compared serum samples from twins using both targeted (Biocrates,) 
and untargeted (Metabolon) mass spectrometry platforms. They found 43 me-
tabolites which were detected with both approaches. These 43 metabolites 
were compared and yielded a mean correlation coefficient of 0.44. The maxi-
mum correlation of r = 0.92 was found for octanoylcarnitine, the minimum corre-
lation of r = 0 for 1-docosahexaenoylglycero-phosphocholine. Seven metabo-
lites, including lipids and an amino acid, showed weak correlations between r = 
0 and r = 0.2.132  
It would constitute a tremendous advantage to use a qTOFMS platform not only 
for semi-quantitative fingerprinting but also for quantitative analysis. One would 
get the opportunity to have a platform which is able to accumulate quantitative 
information of thousands of metabolites in parallel within a single run. Given the 
current scientific knowledge, a more thorough comparison of the two tech-
niques, absolute quantification via MRM mode and relative quantification via 
qTOF-MS in full scan mode, for urine samples is required in order to address 
this question. In this chapter, first the multi-point calibration of the quantitative 
method described in chapter 7 was compared to qTOF-MS measurements in 
untargeted mode, using the same calibration standards and chromatographic 
conditions. With this analysis the quantification performance using stable iso-
tope labeled analogues for both methods (qTOF-MS and QqQ-MS) were 
checked. Analytical values like LLOQ, ULOQ, LOD, linear range and RSD were 
compared between the two techniques. Next, urine samples from the GCKD 
study and NC samples measured with the quantitative method described in 
chapter 7 were measured in semi-quantitative untargeted mode (qTOF-MS). 
Linear correlation, Spearman’s rank correlation coefficients (SCCs) and Bland-
Altmann plots were generated for selected metabolites in order to investigate 
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the quantitative performance of the untargeted platform without using ISs repre-
senting the routine approach of untargeted analysis.  
As mentioned in chapter 7, targeted measurements and manual reintegration of 
the GCKD samples as well as the calibration measurements were done by Lisa 
Ellmann and Katja Dettmer-Wilde. Manual reintegration of the QmDiab samples 
published in Sekula et al 2017 was executed by Lisa Ellmann.44 Data analysis 
of the corresponding calibration and samples was performed together with Katja 
Dettmer-Wilde. Statistical comparison of targeted and non-targeted measure-
ments (published in Sekula et al 2017) was accomplished by Peggy Sekula.  
8.2 Materials and Methods 
8.2.1 Calibration curves and urine sample preparation 
Calibration curves were used in order to compare LOD, LLOQ, ULOQ and line-
ar range for both targeted and untargeted MS platform. Preparation of the dilu-
tion series, stock solutions of the internal standards and the chromatographic 
conditions were the same for both analysis methods. The preparation of the 
dilution series used for both calibrations (fingerprinting and profiling method) is 
described in chapter 7.2.2. Twice the volume of the dilution series was prepared 
and then equally split before the analysis. 
200 urine specimens from the GCKD study as well as 100 NC samples were 
analyzed with both approaches in order to compare the performance. A detailed 
description of the sample cohorts can be found in chapter 6.2.2. For the untar-
geted analysis of the GCKD and NC specimens, samples were measured in 5 
batches consisting of 60 samples each (40 GCKD and 20 NC samples). The 
GCKD and the NC samples were measured in a randomized fashion. For the 
targeted quantitative analysis, urine specimens (GCKD and NC) were pre-
diluted 1:5 with water (PURELAB Plus water). Afterwards, 10 μL of internal 
standard mix were added to 10 μL of pre-diluted urine (for the detailed descrip-
tion see chapter 7.2.2). Finally, the sample was diluted to a final volume of 100 
μL with water. A 1:4 dilution with water was used for the untargeted fingerprint-
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ing analysis of the urine samples. Diluted samples were transferred in 1 mL 
HPLC vials with a 0.5 mL insert (Machery-Nagel, Düren, Germany.  
8.2.2 Instrumentation  
For both, targeted quantitative and untargeted semi-quantitative methods the 
calibration samples were measured with the Atlantis T3 (2.1×150 mm i.d., 3 μm, 
Waters, Eschborn, Germany) reversed-phase column equipped with a C18 se-
curity guard column (Phenomenex, Aschaffenburg, Germany). However, GCKD 
and NC urine samples were measured semi-quantitatively with the KinetexTM 
C18 column. Both calibration and urine samples were only measured in positive 
ionization mode. A detailed description of the applied instruments, parameters 
and gradients can be found in chapter 5.3.1, 5.3.2 and 7.2.4.  
8.2.3 Data analysis 
Data processing for the calibration of the untargeted measurements was per-
formed using DataAnalysis Version 4.1 (Bruker) and QuanLynx V4.1 (Waters). 
First the data were recalibrated and processed in DataAnalysis, and then the 
data were exported in QuanLynx where the selected metabolites were reinte-
grated manually. Data processing of the untargeted measurements of the 
GCKD and NC samples was carried out as described in chapter 6.2.7. Data of 
the five batches were assigned using the in-house RTcorrector and bucket as-
signer (see chapter 5.4.3). Then only the data of selected metabolites were ex-
tracted from the bucket table for the comparison with the targeted data. In order 
to exclude possible batch effects within the untargeted measurements of the 
GCKD samples, hierarchical clustering was performed of all samples as de-
scribed in chapter 6.2.7. Data analysis of the targeted measurements was ac-
complished using Analyst version 1.6.2 (Sciex). Statistical analysis of targeted 
and untargeted measurements was performed using the software described in 
chapter 5.4.1. 
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8.3 Results and Discussion 
8.3.1 Comparison of calibration curves 
In order to compare targeted and untargeted quantification performance, the 
calibration curves measured under the same chromatographic conditions (same 
column, same gradient, same column temperature) were compared. The cali-
bration curves described in chapter 7 for the targeted quantification method 
were compared to untargeted measurements of the same calibration samples.  
Peaks were manually reintegrated for both methods. The manual peak reinte-
gration applied to both methods is usually not used for untargeted measure-
ments due to the huge amount of analytes measured in parallel. However, here 
only six metabolites (PSU, CRE, HIP, CMT, XA and TRP) were selected and 
manually reintegrated for the comparison. Firstly, the comparison was focused 
on these metabolites because PSU, CMT and HIP are interesting metabolites 
associated with renal disease. Secondly, XA and TRP are metabolites from the 
TRP pathway which are also related to renal disease (see chapter 7). Moreover, 
XA was interesting to compare because no appropriate IS was available for the 
quantification. Since serum CRE is the current clinical measure for renal dis-
ease, CRE was also included. For the targeted method the measurements and 
results generated in chapter 7.4.2 were used for the comparison with the finger-
printing method. The calibration results for both methods are summarized in 
Table 8.1 and 8.2. 
Not surprisingly, the targeted quantification resulted in better calibration perfor-
mance than the untargeted method. Nevertheless, the performance of the un-
targeted approach was fairly good. Due to the instrument characteristics (MRM 
vs qTOF), targeted analysis was more sensitive. This means that for the target-
ed method a small increase in analyte concentration causes a larger signal in-
crease. Therefore, the LLOQ for all metabolites were higher when measured 
with the untargeted platform (see Tab. 8.1). The LLOQs ranged from 5.49 nM to 
1,730 nM, whereas for the targeted analysis LLOQs ranged from 1.37 nM to 
65.9 nM. The ULOQs were also higher. In numbers, the ULOQ ranged from 
2,810 nM to 179,000 nM and from 1,140 nM to 270,000 nM for the untargeted 
and targeted analysis, respectively. Due to the higher sensitivity of the targeted 
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instrument, detector saturation is reached earlier in comparison to the untarget-
ed platform. However, CRE is an early eluting metabolite which is only slightly 
retarded. Despite these results, general assumptions are rather critical due to 
the dependency on the used instruments. Moreover, one should keep in mind 
that the QTRAP 4000 used here for the comparison is not state of the art tech-
nology regarding linearity and sensitivity. 
The slopes of the calibration curves from the untargeted analysis were distinctly 
lower in comparison to the targeted method. Only for XA the slope was steeper. 
This is surely the result of lacking an appropriate IS. In particular, slopes ranged 
from 0.3337 to 1.0050 whereas the targeted platform yielded slopes for the cali-
bration curves ranging from 0.522 to 1.62. Additionally, the order of magnitudes 
(OOM) of the linear ranges were lower in comparison to the targeted method of 
all selected metabolites. This also reflects the sensitivity of the two methods. In 
order to check reproducibility of both approaches, 9 calibration levels over the 
complete calibration range were measured in triplicates. For all six metabolites 
measured with the untargeted instrument, RSDs were below 10% in the linear 
range. Therefore, RSDs of the untargeted MS were comparable with the RSDs 
measured in this concentration range with the targeted MS. Except for XA for 
which the LLOQ of the targeted measurements was higher (22 nM) than for the 
untargeted (5.49 nM) (see Tab. 8.1 and 8.2). There the RSD of the targeted 
measurements was 14% in comparison to 5% of the untargeted measurements. 
For XA no appropriate IS was available, therefore KA-d5 was selected instead. 
Consequently, it is more prone to ion suppression which could explain the in-
creased RSDs of the targeted measurements. 
However, it should be kept in mind that for the targeted analysis the Agilent LC 
was used whereas for the untargeted analysis a Dionex instrument was applied. 
Therefore, instrumental differences in void volume, injection mode or needle 
care also influence the chromatographic separation which impacts the calibra-
tion performance. Moreover, differences in electronics and construction designs 
can also affect quantitative performance. Additionally, in untargeted (screening) 
mode, background noise is also detected, whereas in targeted MRM mode 
background noise is suppressed.  
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Table 8.1 Calibration parameters untargeted method. 
Analyte LOD 
(nM) 
Linear range 
(nM) 
Slope Intercept R2 OOM 
CRE 527 1050-33,700 0.7382 170.665 0.9998 1 
PSU 700 1400-179,000 0.5329 174.894 0.9996 2 
CMT 22 44-11,300 0.3337 9.44343 0.9995 3 
TRP 108 1730-111,000 0.3905 -204.639 0.9935 2 
XA 0.172 5.49-2,810 11.716 68.2329 0.9987 3 
HIP 176 176-45,000 1.005 -88.8484 0.9989 2 
 
Table 8.2 Calibration parameters of the targeted method. Adapted from chapter 7.4.2 
Analyte LOD 
(nM) 
Linear range 
(nM) 
Slope Intercept R2 OOM 
CRE 2.06 65.9-270,000 0.96 0.00736 0.9995 4 
PSU 0.684 1.37-44,800 0.573 0.000294 0.9991 4 
CMT 0.687 2.75-11,300 0.522 0.000103 0.9982 4 
TRP 1.69 6.76-13,800 1.62 0.000896 0.9977 4 
XA 0.344 22-2,820 0.71 0.0194 0.9987 2 
HIP 2.75 11.0-1,410 1.3 0.000951 0.9985 2 
 
While analyzing these results, one should keep in mind that these results stem 
from data reintegrated by hand. Further, IS were available for the selected ana-
lytes (except XA) and were used for calibration for both methods (targeted and 
untargeted). Commonly, fingerprinting measures thousands of metabolites in 
parallel. It is a retrospective analysis method for which it is not possible to get IS 
for all measured metabolites. However, if performance of quantification via un-
targeted analysis without IS compares well to targeted quantification with IS this 
would be a tremendous advantage.  
Lu et al., who also investigated targeted an untargeted MS analysis obtained 
similar results.13 The reproducibility of all their tested standards were compara-
ble to their targeted approach with RSD <10% (N=4). TOF (Agilent 6220 TOF)  
sensitivity was also comparable to the triple quadrupole (Thermo Scientific TSQ 
Quantum Ultra). However, it was operated with an unheated ESI source. The 
linear ranges of all compounds ranged over 2 to 3 orders of magnitude on the 
TOF-MS. Lu et al. concluded that the TOF-MS likely has reasonable quantita-
tive performance for many targeted metabolomics applications. However, the 
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untargeted approach provides not automatically fully comparable quantitative 
results to targeted analysis. Although, 10 compounds were measured in positive 
mode the results of only one compound were shown. Moreover, the RSD of on-
ly one concentration level was analyzed and no further details were shown.  
8.3.2 Comparison of population based measurements on targeted 
and untargeted platforms 
Targeted and untargeted measurements of 200 CKD and 100 non-CKD urine 
samples were compared in order to examine the quantitative performance of 
the untargeted platform. Here, the untargeted measurements were performed 
without ISs for the metabolites, which is the routine approach in untargeted 
analysis.  
First, the quality of the untargeted measurements was investigated via hierar-
chical clustering of all 200 GCKD and 100 NC samples. The GCKD and NC 
samples were measured in five batches consisting of 40 GCKD and 20 NC 
samples each. All the samples were measured randomized (for details see sec-
tion 8.2.1). The clustering showed no obvious batch effects since all the sam-
ples, GCKD and NC, from all five batches clustered randomly and not batch 
wise (see Figure 8.1). The main resulting clusters are marked in blue, green 
and red. Hence, the quality of the data was suitable for a comparison with the 
targeted data. Quality of the quantitative data was shown by the calibration pa-
rameter and recovery described in chapter 7.  
For the comparison between the two platforms, TRP, XA, PSU and CMT were 
used. These are prominent metabolites which were found in most of the 200 
GCKD and 100 NC samples with concentrations below detector saturation. 
CRE and HIP were not analyzed because these metabolites were above ULOQ 
in both methods in the GCKD and NC samples.   
The linear range of the untargeted method determined in chapter 8.3.1 was 
compared to the selected metabolites concentrations of the GCKD and NC 
samples. The concentration for PSU and CMT lay within the linear range for all 
GCKD and NC samples. For TRP, 77 GCKD samples (39% of the samples) and 
20 NC samples (20% of the samples) were below the LLOQ. Moreover, for one 
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GCKD sample TRP was not detectable. For XA, 72 GCKD (39% of the sam-
ples) and 30 NC (32% of the samples) samples were below the LLOQ. Addi-
tionally, for 17 GCKD and 6 NC samples XA was not detectable. Therefore, 
most of the GCKD and NC samples were in the linear range of the untargeted 
platform. However, more GCKD samples were outside the linear range of the 
untargeted platform than NC samples. For PSU, CMT, TRP as well as XA one 
GCKD sample each was below the LLOQ of the targeted method. All NC sam-
ples were within the linear range of the targeted platform for all selected metab-
olites. Yet, all samples were used for the comparison because LLOQ and 
ULOQ are usually not available for routine fingerprinting data.  
 
 
Figure 8.1:Hierachical cluster analysis of fingerprinting data of 200 GCKD and 100 NC samples 
measured with untargeted LC-qTOFMS. The main resulting clusters are marked in blue, green 
and red.  
In order to determine the quantification performance of the untargeted platform, 
Spearman’s rank correlation coefficients (SCC) were calculated for the selected 
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metabolites. For the GCKD samples, targeted and untargeted measurements of 
PSU yielded a SCC of 0.67, while the corresponding coefficients for XA, CMT 
and TRP were 0.83, 0.87, and 0.85, respectively. The lower SCC for PSU is 
probably due to its low retention time (1.3 min), at which many metabolites elute 
simultaneously. Thus, ion suppression might affect the quantification. Bland-
Altmann plots of the ranks of targeted and untargeted measurements revealed 
a mean difference of -1.0, -0.7, 0.0 and 0.0 for PSU, CMT, TRP and XA, re-
spectively. 95% confidence intervals ranged from 90.8 to -93.8, 56.1 to -57.5, 
60.5 to -60.5, and 57.7 to -57.7 for PSU, CMT, XA and TRP, respectively (see 
Fig. 8.3 E-H). Confidence intervals were rather high, but no systematic bias was 
observed. 
 
 
Figure 8.2: Representative chromatogram of a GCKD urine sample measured in untargeted 
mode by LC-qTOF MS. XIC of PSU (red line) is depicted on the left and the corresponding 
mass spectrum on the right. At 1.3 min coelution of unknown metabolites with PSU is observa-
ble. 
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Figure 8.3: Comparison of ranks of targeted and untargeted mass spectrometric measurements 
of pseudouridine (PSU), C-mannosyltryptophan (CMT), tryptophan (TRP) and xanthurenic acid 
(XA) in individuals with chronic kidney disease (GCKD) with the corresponding Bland-Altmann 
plots (E-H). SCC: Spearman correlation coefficient corresponding to slope of displayed regres-
sion line of rank transformed measurements. 
As mentioned above for fingerprinting analysis no IS were used to correct for 
ion suppression. The SCC of PSU, CMT, XA and TRP for NC samples were 
investigated. These samples represent average diet, environmental exposures 
and medication. The SCC of PSU for the NC samples is 0.73. For CMT the 
8. Comparison of fingerprinting LC-HRTOF-MS and LC-QqQMS profiling data 108 
 
SCC was 0.95, for XA 0.94 and for TRP 0.90. This means that targeted and 
non-targeted measurements showed a very good correlation. In comparison to 
the SCCs of the GCKD samples, targeted and non-targeted measurements of 
NC samples correlate much better. Bland-Altmann plots of the ranks of targeted 
and untargeted MS measurements revealed a mean difference of -1.0, 0.0, -0.6 
and 0.0 for PSU, CMT, XA and TRP, respectively. 95% confidence intervals 
ranged from 36.6 and -38.5, 18.4 and -18.4, 18.1 and -19.3 as well as 26.0 and 
-26.0, PSU, CMT, XA and TRP respectively (see Fig. 8.4 E-H). Confidence in-
tervals are also rather high. However, no systematic bias was observed.  
Chromatographic separation as well as the concentration range of the analytes 
in the samples affect correlation. However, also the availability of a stable iso-
tope labeled analog as IS for the targeted analysis, which was not the case for 
XA, influence the correlation between targeted and untargeted measurements. 
Nevertheless, the results indicate that relative quantification by untargeted 
screening is reliable in large studies with this instrument setup.  
 
 
8. Comparison of fingerprinting LC-HRTOF-MS and LC-QqQMS profiling data 109 
 
 
Figure 8.4: Comparison of ranks of targeted and untargeted mass spectrometric measurements 
of pseudouridine (PSU), C-mannosyltryptophan (CMT), xanthurenic acid (XA) and tryptophan 
(TRP) in apparently healthy individuals from the national cohort study (NC) with the correspond-
ing Bland-Altmann plots (E-H). SCC: Spearman correlation coefficient corresponding to slope of 
displayed regression line of rank transformed measurements. 
In Sekula et al. (2017), targeted and untargeted measurements of 111 samples 
of non-CKD patients from the QMDiab study were compared.44 These targeted 
measurements were performed using the quantitative method described in 
chapter 7, whereas untargeted measurements were carried out by Metabolon. 
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For pseudouridine they found a SCC of 0.67 for the correlation of targeted and 
untargeted measurements in plasma. The correlation for urine samples was 
even better with a SCC of 0.90. For CMT the SSC was 0.69 in plasma and 0.89 
in urine. For CRE the SCC was 0.68 in plasma and 0.95 in urine. This is espe-
cially impressive as targeted and untargeted measurements were performed in 
different laboratories using different equipment and sample preparation proto-
cols.  
Sekula et al also highlighted previous studies which compared targeted and 
untargeted measurements.44,129-132 They came to the conclusion that biomarker 
discovery by untargeted methods should be validated quantitatively by targeted 
approaches.44 Besides, they pointed out that general assumption across 
metabolomics platforms are challenging. Further they emphasize the im-
portance of using absolute quantification results in order to validate biomarker 
discoveries.44  
8.4 Conclusions 
The linear range determined with selected metabolites for the untargeted plat-
form proved to be sufficient in comparison to the targeted platform. Reproduci-
bility in the linear range is very good in comparison to the targeted approach. 
Moreover, targeted and untargeted measurements of urine samples from the 
NC yielded a very good agreement, whereas the agreement of GCKD samples 
was lower but still adequate, which was attributed to stronger matrix effects for 
the GCKD samples.  
Overall the correlation of targeted and untargeted platforms is surely instrument, 
metabolite and concentration dependent. Moreover, chromatographic separa-
tion and ion-suppression are also affecting the correlation. However, it certainly 
is impossible to separate all detected metabolites of urine samples measured 
with the untargeted method, in order to reduce ion suppression. By adding ISs 
to the matrix under investigation, untargeted measurements could provide sup-
plementary quantitative insights into preselected metabolites. Nevertheless, 
quantification by fingerprinting without using ISs could be sufficient enough for 
some metabolites to replace targeted. This surely depends on the aim and 
 111 
 
scope of the analytical question under investigation. Nevertheless, general as-
sumptions across different platforms are critical and are surely dependent on 
the type of instruments used. Since even small variations in measurements can 
result in drastic deviations of the results as demonstrated by Sekula et al. for 
the calculation of the fractional excretion, it would be advisable, as it is the case 
for every quantification, to obtain a secondary analysis with an independent 
platform to get unbiased and reliable quantitative results. Despite, this approach 
would combine both quantitative and untargeted information which is a tremen-
dous advantage over targeted analysis. 
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9.  Conclusion and Perspectives 
This thesis clearly demonstrates the vast potential of high-resolution LC-MS in 
untargeted metabolomics of complex biological matrices like urine. Through the 
introduction of pre-acquisition dilution to a uniform creatinine concentration, sig-
nificant improvements were achieved in both sample classification and metabo-
lite identification. Further promising accomplishments were the implementation 
of a quantitative LC-MS method to investigate urinary metabolites associated 
with renal disease in order to reveal new insights into pathophysiological mech-
anisms and the quantitative comparison of LC-qTOF-MS and LC-qQq-MS in 
order to investigate the combined potential of targeted and untargeted LC-MS 
metabolomics on a single platform.  
The comparison of different pre-acquisition dilution strategies of urine clearly 
demonstrated that dilution to a uniform creatinine concentration outperforms all 
other tested strategies. This pre-acquisition strategy was the only method which 
showed no correlation of MVs with creatinine concentration or osmolality val-
ues. It yielded the highest percentage of significant differential metabolites and 
was the sole strategy for which the hierarchical cluster analysis reliably as-
signed the urine specimens of controls and CKD patients to their respective 
clusters. Furthermore, the proposed normalization method allows reliable sam-
ple classification as demonstrated for several different patient cohorts. Appar-
ently, dilution to a uniform creatinine concentration is the only tested method 
which balances the high variability in metabolite abundance between samples 
sufficiently enough to eliminate analytical consequences like ion suppression, 
detector saturation and column overloading.  The results obtained underscore 
the improved reproducibility and applicability of pre-acquisition dilution to a uni-
form creatinine concentration and, thus, justify the associated time and labor. 
The quantitative LC-qQqMS method implemented in this thesis comprised sig-
nificantly discriminating metabolites between CKD patients and apparently 
healthy specimen which had been identified by the aforementioned project. This 
quantitative method expands the one published by Zhu et al. in 2011. It was 
successfully applied to the analysis of CRE, CMT and PSU in the study of 
Sekula et al. 2017 and for the analysis of CRE and CRT in the study of Wall-
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meier et al. 2017. Within these studies the excellent quality of the developed 
method was demonstrated in different matrices.  
A further key aspect of this thesis was the comparison of targeted LC-qQq-MS 
and untargeted LC-qTOF-MS measurements of urine samples elucidating the 
quantitative performance of the used untargeted platform. Merging targeted and 
untargeted analysis of samples within one run would be a tremendous ad-
vantage over separate quantitative MRM- and untargeted measurements. Re-
sults from the comparison showed that for the selected metabolites high corre-
lations were yielded. However, the correlations are dependent on the instru-
ments, the metabolites and on the chromatographic separation. Therefore, the 
application of untargeted analysis of urine samples without using IS for the rela-
tive quantification is limited. Still, quantification via fingerprinting LC-MS results 
in semi-quantitative data, thus verification by an LC-MS measurement in MRM 
mode is advisable. Moreover, as already stated by Sekula et al. 2017 general 
assumptions across platforms are critical. However, quantification by fingerprint-
ing without using ISs could be sufficient enough for some metabolites to replace 
targeted analysis. This surely would be dependent on the aim and scope of the 
analytical question under investigation.  
For fingerprinting analysis by LC-MS further studies need to focus on the im-
plementation of identification tools to simplify the identification of unknowns. 
Therefore, more comprehensive MS metabolite libraries are required as well as 
more comprehensive identification tools like the compound crawler from Bruker. 
In order to distinctly identify unknown metabolites, the supply of proper refer-
ence compounds must be increased. Additionally, data storage becomes more 
and more an issue due to increasing data file sizes with LC-MS measurements 
(full scan and MS/MS LC-MS).  
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11.  Appendix 
Table 11.1. List of 72 tentative metabolite identifications out of 130 features that differed signifi-
cantly in abundance between CKD patients and healthy controls. Each metabolite is character-
ized by retention time and the m/z value. For each tentative metabolite, a sum formula was cal-
culated and the mass error in mDa and the mSigma value as a measure for the isotopic fit are 
listed. Wherever possible, a tentative identification was made. Therefore, each potential me-
tabolite was searched in ChEBI. Some metabolites were additionally found in HMDB and 
METLIN. For some features, two or more assignments were possible. Reprinted from Vogl et al. 
2016.
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Table 11.2. Figures of merit of the different tested trainings and test sets employed for the ran-
dom forest classification. Reprinted from Vogl et al. 2016.
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Table 11.3. Stock solutions of the metabolites included in the extended quantitative method with 
the applied solvent and the respective concentration.  
AM 1 solvent c [mM] 
Kynurenic acid 100% H2O 12.20 
DL-Kynurenine 100% H2O 11.24 
Nicotinamide  100% MeOH 46.70 
DL-Tryptophan 100% MeOH 2.64 
Xanthurenic acid 10% 1M NaOH 56.90 
Quinolinic acid 50% MeOH 60.60 
Anthranilic acid 50% MeOH 54.00 
3-Hydroxyantranilic acid 85% MeOH  9.66 
Indole-3-acetic acid 50% MeOH 30.77 
Serotonin  50% MeOH 9.12 
DL-lndole-3-lactic acid 50% MeOH, 50%  0.1% HCOOH 9.40 
Indole-3-propionic acid 50% MeOH, 50%  0.1% HCOOH 45.80 
Indole-3-carboxaldehyde 50%MeOH, 48% H2O, 2% HCOOH 54.70 
Indole-3-pyruvic acid 100% MeOH 12.75 
Tryptamine 100% MeOH 30.46 
Tryptophol 100% MeOH 31.90 
Nicotinic acid  100% MeOH 81.55 
Melatonin 100% MeOH 20.60 
3-Hydroxy-DL-Kynurenine 100% MeOH 4.90 
5-Hydroxyindole-3-acetic 
acid 
100% MeOH 15.80 
AM 2   
Uric acid 20% 1M NaOH  11.18 
3-Indoxylsulfate 0.1% HCOOH 18.15 
Creatine 100% H2O 14.01 
Creatinine 50% MeOH 98.10 
ß-Pseudouridine 100% H2O 102.14 
Hippuric acid 50% MeOH 64.96 
Guanidinoacetic acid 100% H2O 19.98 
c-Mannosyltryptophan 100% H2O 10.00 
Xanthine 30% NH4OH (28% NH3 in H2O) 23.50 
Hypoxanthine 100% H2O 5.80 
Methylxanthine 20% NH4OH (28% NH3 in H2O) 23.40 
 AM 3 
  
1-Methylinosine 100% H2O 4.10 
1,7-Dimethylxanthine 100% H2O 5.72 
Tiglylcarnitine 100% H2O 9.76 
Methylguanine 20%  MeOH, 5% 1M NaOH 7.71 
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13. Summary 
With recent instrumental improvements, untargeted high-resolution liquid chro-
matography mass spectrometry (LC-MS) has been increasingly applied to the 
analysis of complex biological matrices such as urine. The latter is a preferred 
matrix in large scale metabolomics studies, because it can be obtained non-
invasively in sufficient quantities. However, the widely varying concentrations of 
urine metabolites, mostly due to different fluid intake, pose analytical challeng-
es, such as ion suppression, detector saturation, column overload or failure to 
detect low abundant metabolites. In this doctoral thesis, both targeted and un-
targeted analysis of urine by LC-MS was investigated to address some of these 
challenges. Further, the question was addressed if untargeted fingerprinting of 
urine specimens is adequate for the quantitative analysis of these specimens.   
First, five different dilution and normalization strategies of spot urinary speci-
mens were compared. Specimens were adjusted either to a uniform creatinine 
concentration or osmolality without any further normalization of the acquired 
data, or they were uniformly diluted and post-acquisition normalized to creati-
nine, osmolality, or sum of all integrals. Spot urine specimens from both an ap-
parently healthy cohort and two different cohorts suffering from chronic kidney 
disease (CKD) were investigated to test the effect of the various strategies on 
sample classification. The advantages of pre-acquisition dilution of urine to a 
fixed creatinine concentration in the acquisition of metabolite fingerprints by LC 
coupled to a high resolution time-of-flight mass spectrometer (LC-HRTOFMS) 
were demonstrated. These included the absence of significant correlations of 
missing values with either the original urine creatinine concentration (r = 0.216, 
p = 0.133) or osmolality (r = - 0.074, p = 0.608). Moreover, pre-acquisition dilu-
tion to a uniform creatinine concentration was the only method to correctly as-
sign urine specimens of controls (national cohort, NC) and CKD patients to their 
respective clusters in hierarchical cluster analysis, while the other dilution and 
normalization methods yielded indistinct clusters. Therefore, time and labor as-
sociated with pre-acquisition dilution to a uniform creatinine concentration are 
more than justified.  
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Next, a targeted liquid chromatography triple quadrupole mass spectrometry 
(LC-QqQMS) method for the quantification of urine metabolites associated with 
CKD was developed. Some of these metabolites had been identified during the 
testing of different pre-acquisition dilution and normalization strategies. The dy-
namic range of the method showed adequate sensitivity for all urine metabolites 
investigated. The lower limits of quantification (LLOQs) ranged between 0.04 
nM to 11 nM except for creatinine (CRE), creatine (CRT), hypoxanthine (HX) 
and xanthurenic acid (XA), which featured LLOQs of 65.9 nM, 700 nM, 87.8 nM, 
and 22.0 nM, respectively. Spike-in experiments yielded recoveries of 86% to 
121%. The method was applied successfully to the determination CRE, C-
mannosyltryptophan (CMT) and pseudouridine (PSU) in urine (Sekula et al. 
2017, Scientific Reports 7(1): 17400) and to CRE and CRT in plasma (Wall-
meier et al. 2017, Journal of Proteome Research 16(4): 1784-1796). 
Finally, targeted and untargeted measurements of urine specimens were com-
pared with respect to the quantitative performance of untargeted measure-
ments. Combining both targeted and untargeted analysis of urine in a single 
analysis would constitute a tremendous saving of time and resources. First, cal-
ibration curves of selected metabolites were compared, measured in both full 
scan and MRM mode on a Bruker Maxis Impact quadrupole time-of-flight and a 
Sciex 4000 QTRAP mass spectrometer, respectively. The LLOQs on the former 
instrument ranged from 5.49 nM to 1730 nM, whereas the corresponding range 
on the latter instrument was 1.37 nM to 65.9 nM. The linear ranges were also 
narrower for the untargeted than the targeted method. Reproducibility over the 
linear range compared well to the targeted approach. All relative standard devi-
ation (RSD) values for the selected metabolites were below 10%. Next, targeted 
and untargeted measurements of 200 CKD and 100 non-CKD urine specimens 
were compared to examine the quantitative performance of the untargeted plat-
form. For the CKD samples, targeted and untargeted measurements of PSU, 
XA, CMT and tryptophan (TRP) yielded Spearman’s rank correlation coeffi-
cients ranging from 0.67 to 0.87, while the corresponding coefficients for urine 
specimens from apparently healthy individuals ranged from 0.73 to 0.95. PSU 
yielded consistently the weakest correlation coefficient, most likely due to matrix 
effects as a consequence of its low retention and, thus, co-elution with many 
other analytes. It is concluded, that the correlation of quantitative data gained by 
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targeted and non-targeted analysis depends on the instruments and methods 
used as well as the metabolites and their abundance. 
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14. Zusammenfassung 
Auf Grund von instrumentellen Verbesserungen hat die hochauflösende, nicht 
zielgerichtete Flüssigchromatographie - Massenspektrometrie (LC-MS Finger-
printing-Analyse) rasant an Bedeutung in der Analyse von komplexen biologi-
schen Matrices wie Urin gewonnen. Urin ist eine sehr interessante Proben-
matrix für große Kohorten-Studien, da sie nicht invasiv und in ausreichenden 
Mengen gesammelt werden kann. Allerdings birgt die Analyse von Urin auch 
viele Herausforderungen. Die stark variierenden Konzentrationen an Metaboli-
ten, die unter anderem aus unterschiedlicher Flüssigkeitsaufnahme resultieren, 
führen zum Beispiel zu Ionenunterdrückung, Detektorsättigung, Überladung der 
Säule oder dem Unvermögen, niedrig abundante Metaboliten zu detektieren. In 
dieser Doktorarbeit wurden sowohl die zielgerichtete als auch die nicht zielge-
richtete Analyse von Urinproben mittels LC-MS untersucht, um einige dieser 
Herausforderungen zu adressieren. Außerdem wurde der Frage nachgegan-
gen, ob eine nicht zielgerichtete Analyse von Urinproben die gezielte quantitati-
ve Analyse von Metaboliten im Urin ersetzen kann.  
Zuerst wurden fünf Verdünnungs- und Normalisierungsstrategien für die Analy-
se von Spontanurin mittels der LC gekoppelt an ein hochauflösendes Flugzeit-
massenspektrometer (LC-HRTOFMS) verglichen. Die Proben wurden entweder 
auf eine konstante Kreatinin-Konzentration beziehungsweise Osmolalität einge-
stellt, ohne anschließende Normalisierung der aufgenommenen Daten, oder wie 
es die übliche Praxis ist, einheitlich verdünnt und nach der Messung wurden die 
Daten auf Kreatinin, Osmolalität oder die Summe über alle Integrale normali-
siert. Dabei wurde der Effekt dieser verschiedenen Strategien auf die Proben-
klassifizierung getestet. Als Proben wurde Spontanurin von einer vermeintlich 
gesunden Kohorte (Nationale Kohorte, NC) und von zwei verschiedenen Pati-
entenkohorten, die unter chronischer Nierenerkrankung (CKD) litten, verwendet. 
Hierbei konnten die Vorteile der Verdünnung von Urin vor der Datenaufnahme 
auf eine konstante Kreatinin-Konzentration für einen metabolischen Fingerprint 
mittels LC-MS demonstriert werden. Nur die Proben, die auf eine konstante 
Kreatinin-Konzentration verdünnt wurden, zeigten weder eine Korrelation der 
Anzahl an fehlenden Messwerten mit der ursprünglichen Kreatinin-
Konzentration (r = 0,216, p = 0,133) noch mit der Osmolalität (r = - 0,074, p = 
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0,608). Zudem erzielte diese Methode unter allen getesteten Vorgehensweisen 
prozentual die meisten signifikant diskriminierenden Features zwischen Patien-
ten mit CKD und Kontrollen. Die zweitbeste Methode hinsichtlich der Prozent-
zahl an diskriminierenden Features war die konstante Verdünnung in Kombina-
tion mit der nachfolgenden Normalisierung auf die Summe aller Integrale. Die 
Überlegenheit der Verdünnung vor der Messung auf eine einheitliche Kreatinin-
Konzentration wurde zusätzlich durch eine hierarchische Cluster-Analyse ge-
zeigt. Diese konnte die Kontrollen und die CKD Patienten zuverlässig clustern. 
Im Gegensatz dazu erzielten die anderen Verdünnungs- und Normalisierungs-
methoden keine einheitlichen Cluster. Deshalb kann die einheitliche Verdün-
nung (z.B. ¼) in Kombination mit der Normalisierung auf Kreatinin oder Os-
molalität nicht empfohlen werden. Die Auswirkungen der großen Varianz der 
Metabolit-Konzentration zwischen den Proben auf Ionenunterdrückung, Detek-
torsättigung und Überladung der Säule werden durch diese Normalisierungsme-
thoden nicht ausreichend erfasst. Darüber hinaus ermöglicht die vorgeschlage-
ne Normalisierungsmethode die zuverlässige Probenklassifizierung, was an-
hand verschiedener Patienten-Kohorten gezeigt wurde. Außerdem konnten die 
meisten differenziellen Features, die CKD Patienten von vermeintlich gesunden 
Kontrollen unterschieden, bekannten Metaboliten zugeordnet werden. All diese 
Ergebnisse unterstreichen die überragende Reproduzierbarkeit und Anwend-
barkeit der Verdünnung auf eine einheitliche Kreatinin-Konzentration vor der 
eigentlichen Messung und rechtfertigen den damit verbundenen Zeit- und Ar-
beitsaufwand.  
Ein weiterer Fokus dieser Arbeit lag in der Weiterentwicklung einer LC-QqQMS 
basierten Methode, die ursprünglich von Zhu et al. (Analytical and Bioanalytical 
Chemistry 401: 3249-3261) für die Bestimmung von Tryptophanmetaboliten 
beschrieben worden war, für die gezielte Quantifizierung von insgesamt 33 Me-
taboliten im Urin, welche mit CKD in Verbindung gebracht werden. Der dynami-
sche Bereich der weiterentwickelten Methode zeigte eine angemessene Nach-
weisempfindlichkeit für alle hinzugefügten Metaboliten in der Analyse von Urin-
proben. Die Bestimmungsgrenzen (LLOQs) lagen bei 0,04 nM bis 11 nM, außer 
für Kreatinin (CRE), Kreatin (CRT), Hypoxanthin (HX) und Xanthurensäure 
(XA), welche eine untere Bestimmungsgrenze von 65,9 nM, 700,0 nM, 87,8 nM 
bzw. 22,0 nM aufwiesen. Die in einem Spike-in Versuch ermittelten Wiederfin-
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dungsraten für einen Teil der in der Methode enthaltenen Metaboliten lagen 
zwischen 86% und 121%. Die Methode wurde erfolgreich für die Quantifizierung 
von Kreatinin, C-Mannosyltrptophan (CMT) und Pseudouridin (PSU) in Urin 
(Sekula et al. 2017, Scientific Reports 7(1): 17400) sowie von Kreatinin und 
Kreatin in Plasma (Wallmeier et al. 2017, Journal of Proteome Research 16(4): 
1784-1796) verwendet. 
Zuletzt wurden zielgerichtete und nicht zielgerichtete Messungen von Urinpro-
ben in Hinblick auf die quantitative Leistungsfähigkeit der nicht zielgerichteten 
Messungen verglichen. Es wäre ein enormer Vorteil, wenn nicht zielgerichtete 
Analysen einer Probe auch eine zuverlässige Quantifizierung der identifizierten 
Metaboliten erlauben würden. Dafür wurden zuerst die Kalibrationskurven von 
ausgewählten Metaboliten für die beiden Plattformen verglichen. Es wurde ge-
zeigt, dass der lineare Bereich der beiden Plattformen gut übereinstimmt. Die 
unteren Bestimmungsgrenzen (LLOQ) lagen zwischen 5,49 nM und 1.730 nM, 
wohingegen jene für die gezielten Analysen mit 1,37 nM bis 65,9 nM erwar-
tungsgemäß niedriger waren. Für alle ausgewählten Metaboliten waren die 
Größenordnungen der linearen Bereiche der nicht-zielgerichteten Methode 
niedriger im Vergleich zur zielgerichteten Methode, wodurch die höhere Sensiti-
vität der zielgerichteten Methode aufgezeigt wurde. Die Reproduzierbarkeit im 
linearen Bereich war mit relativen Standardabweichungen von <10% im Ver-
gleich zur gezielten Herangehensweise sehr gut. Als nächstes wurden zielge-
richtete und nicht zielgerichtete Messungen von 200 CKD und 100 nicht-CKD 
Urinproben verglichen, um die quantitative Leistungsfähigkeit der nicht zielge-
richteten Plattform zu untersuchen. Die zielgerichteten und nicht zielgerichteten 
Messungen von PSU, CMT, XA und Tryptophan (TRP) in den CKD Urinproben 
zeigten eine gute Übereinstimmung mit Spearman‘schen Rangkorrelationskoef-
fizienten (SCC) von 0,67 bis 0,87. Für Proben gesunder Probanden wurde eine 
noch bessere Korrelation zwischen der zielgerichteten und nicht zielgerichteten 
Plattform festgestellt; die Rangkorrelationskoeffizienten für PSU, CMT, XA und 
TRP betrugen 0,73, 0,95, 0,94 und 0,90. Insgesamt kann festgehalten werden, 
dass die Korrelation der zielgerichteten und nicht zielgerichteten Plattformen 
sicherlich abhängig von den angewendeten Instrumenten und Methoden sowie 
den Metaboliten und deren Konzentration ist. Daher ist eine Verallgemeinerung 
der Resultate nur sehr eingeschränkt möglich. 
